Banner
RESEARCH POSTER PRESENTATIONS SESSION II: Monday, 5 November 2012

Click on the topic below to view posters

SESSION II – MONDAY, 5 NOVEMBER
SET-UP: Monday, 5 November 2012, 15:15 – 15:30
POSTER DISPLAY HOURS: Monday, 5 November 2012, 15:30 - 19:30
POSTER AUTHOR DISCUSSION HOUR: Monday, 5 November 2012, 18:30 – 19:30
DISMANTLE: Monday, 5 November 2012, 19:30

CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies

PCV1

ANGIOTENSIN RECEPTOR BLOCKERS AND THE RISK OF MYOCARDIAL INFARCTION: NETWORK META-ANALYSIS AND PROBABILITY RANKING

 

Mazumder D, Arora A, Bhutani MK, Pathak P, Siddiqui MK
Heron Health Private Ltd., Chandigarh, India

PCV2

COMPARATIVE EFFICACY AND SAFETY ANALYSIS OF ATRIAL FIBRILLAION PATIENTS TREATED WITH DABIGATRAN IN RE-LY STUDY (CHADS 2 SCORE OF 3 OR GREATER ) VERSUS RIVAROXABAN IN ROCKET-AF

 

Rasty S1, Soliman W2, Taheri R3
1Roosevelt University, Buffalo Grove, IL, USA, 2Consultant, Fort lee, NJ, USA, 3West Coast University, Los Angeles, CA, USA

PCV3

PREVALENCE, ASSOCIATED COMORBIDITIES AND TREATMENT PATTERNS AMONG CHRONIC KIDNEY DISEASE PATIENTS: AN ANALYSIS USING UK GPRD DATA

 

Jick S1, Hagberg KW1, O'Donoghue D2, Jameson K3, Ambegaonkar BM4
1Boston University School of Medicine, Lexington, MA, USA, 2Salford Royal NHS Foundation Trust, Salford, UK, 3MSD Ltd., Hoddesdon, UK, 4Merck & Co. Inc., Whitehouse Station, NJ, USA

PCV4

THE OPTIMAL INTERVAL OF FRAMINGHAM RISK SCORE TO DETECT CARDIOVASULAR DISEASE IN HEALTHY ADULTS: A LARGE COHORT STUDY IN JAPAN

 

Takahashi O1, Ohde S2, Deshpande GA2, Fukui T1
1St.Luke's International Hospital, Tokyo, Japan, 2St.Luke's Life Science Institute, Tokyo, Japan

PCV5

COMPARISON OF ATRIAL MEASUREMENTS AND ESTIMATIONS OF TRANSMITRAL REGURGITATION USING THREE-DIMENSIONAL AND CONVENTIONAL ECHOCARDIOGRAPHY IN DOGS

 

Poulsen Nautrup B1, Schultheiss S2, Poulsen Nautrup C2
1EAH Consulting, Juelich, Germany, 2Ludwig-Maximilians-University Munich, Munich, Germany

PCV6

COMPARISON RIVAROXABAN WITH OTHER ANTITHROMBOTIC AGENTS: EFFECTIVENESS AND SAFETY OF PROPHYLACTIC ANTITHROMBOTIC AGENTS AFTER MAJOR ORTHOPEDIC SURGERIES IN TAIWAN

 

Chang WY1, Hsu HC2, Wu CH2, Chen PS2, Wu MT1
1Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan

PCV7

A MIXED TREATMENT COMPARISON (MTC) TO COMPARE THE EFFICACY OF ANTI-THROMBOTIC AGENTS IN THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM (SE) IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF)

 

Edwards SJ, Hamilton V, Nherera L, Trevor N, Barton S
BMJ Group, London, UK

PCV8

ASSESSMENT OF 30-DAY REHOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME WHO RECEIVED PERCUTANEOUS CORONARY INTERVENTION: A COMPARATIVE EFFECTIVENESS STUDY OF CLOPIDOGREL AND PRASUGREL

 

Bae JP1, Faries DE1, Ernst FR2, Lipkin C2, Zhao Z1, Moretz C2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Premier Healthcare Alliance, Charlotte, NC, USA

PCV9

ASSOCIATION BETWEEN PERSISTENCE WITH STATINS AND REDUCTION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL: ANALYSIS OF REAL-LIFE DATA FROM COMMUNITY SETTINGS

 

Shalev V, Goldstein I, Porath A, Chodick G
Maccabi Healthcare Services, Tel Aviv, Israel

PCV10

WITHDRAWN

 

 

PCV11

INDIRECT TREATMENT COMPARISON (ITC) OF NOVEL ORAL ANTICOAGULANTS FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION

 

Pechlivanoglou P1, Le HH1, Engelfriet PM2, Redekop WK3, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The Netherlands

PCV12

EFFICACY OF HEART FAILURE PHARMACOLOGICAL TREATMENT CLASSES AND COMBINATIONS: NETWORK META-ANALYSES

 

Vieira MC1, Ellis AG1, Lowy A2, Deschaseaux C2, Jansen JP1
1MAPI Consultancy, Boston, MA, USA, 2Novartis Pharma AG, Basel, Switzerland

PCV13

ARE STATINS EFFECTIVE TO PREVENT FIRST NON-FATAL MYOCARDIAL INFARCTION IN REAL LIFE IN A LOW-RISK COUNTRY? A POPULATION-BASED CASE-REFERENT STUDY USING THE PGRX INFORMATION SYSTEM

 

Grimaldi-Bensouda L1, Rossignol M2, Khachatryan A3, Abenhaim L3
1LA-SER, Paris, Paris, France, 2LA-SER Centre for Risk Research Inc., Montreal, Montreal, Canada, 3LA-SER Europe Ltd., London, London, United Kingdom

PCV14

COLESEVELAM FOR THE TREATMENT OF HYPERLIPIDEMIA: A RETROSPECTIVE ‘REAL-WORLD' ANALYSIS FROM AN INTEGRATED HEALTH SYSTEM

 

Romanelli R1, Leahy A1, Jukes T1, Ye X2, Luan A2, Ishisaka D1
1Sutter Health, San Francisco, CA, USA, 2Daiichi Sankyo, Parsippany, NJ, USA

PCV15

BIAS-CORRECTED INDIRECT COMPARISON META-ANALYSIS OF NEW ORAL ANTICOAGULANT IN ATRIAL FIBRILLATION

 

Cucherat M
Faculté de Médecine Laennec, Lyon, France

PCV16

USE OF ACE INHIBITORS IN SERBIA IN 2009 AND 2010

 

Milijasevic B, Tomic Z, Sabo A, Horvat O
Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia and Montenegro

PCV17

A CROSS-SECTIONAL ASSESSMENT OF ATRIAL FIBRILLATION MANAGEMENT AMONG FRENCH PATIENTS IN PRIMARY CARE

 

Sabouret P1, Willems C2, Cotté FE3, Marie P2, Mercier F4, Depret-Bixio L2, Blin P5
1Pitié-Salpétrière Hospital, Paris, France, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 3Bristol-Myers Squibb, Rueil-Malmaison , France, 4StatProcess, Port-Mort, France, 5Bordeaux University, Bordeaux, France

PCV18

CARDIOVASCULAR RISK ASSESSMENT USING FRAMINGHAM RISK EQUATION IN NEWLY DIAGNOSED TYPE 2 DIABETIC INDIAN PATIENTS

 

Sujata G1, Tiwari P2, Bhansali A3
1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, Punjab, India, 2National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. NAGAR, Punjab, India, 3Post Graduate Institute of Medical Education and Research, Chandigarh, India

PCV19

THE BURDEN OF DIABETES MELLITUS IN BELGIUM: A RETROSPECTIVE DATABASE STUDY

 

Lamotte M, Chevalier P, Gerlier L
IMS Health, Vilvoorde, Belgium

CARDIOVASCULAR DISORDERS – Cost Studies

PCV20

POSSIBLE BUDGET IMPACT OF INTERNAL REFERENCE PRICING FOR STATINS IN TURKEY

 

Kockaya G1, Tuna E2, Atikeler K3
1Health Economics and Policy Association, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey, 3Ankara University, Ankara, Turkey

PCV21

BUDGET IMPACT ANALYSIS OF INTRODUCING OF PCMV-VEGF165 FOR TREATMENT OF CRITICAL LIMB ISCHEMIA FROM THE RUSSIAN HEALTH CARE SYSTEM PERSPECTIVE

 

Yagudina R1, Kulikov A2, Kogon L3
1First Moscow State Medical University named after I. M. Sechenov, Moscow, Moscow, Russia, 2First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia, 3FGBU NCESMP Minzdravsocrazvitiya RF, Moscow, Russia, Moscow, Russia

PCV22

A SIMPLE RISK SCORE IDENTIFIES INDIVIDUALS, IN EUROPEAN SETTINGS, MORE LIKELY TO INCUR HIGHER MEDICAL COSTS

 

Guda S, Alperin P, Schuetz CA
Archimedes, Inc., San Francisco, CA, USA

PCV23

BETA BLOCKERS FOR TREATMENT OF CHRONIC HEART FAILURE IN SPAIN: REVIEW OF THE ECONOMIC EVIDENCE AND EFFICIENCY ANALYSIS

 

Polanco C, García-Jurado L
Merck SL, Madrid, Spain

PCV24

ECONOMIC ANALYSIS OF BEMIPARIN AND ENOXAPARIN USED FOR THROMBOSIS AND EMBOLISM PREVENTION IN ORTHOPEDIC PATIENTS IN RUSSIA

 

Ryazhenov VV, Gorokhova SG
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCV25

HOSPITALIZATION COSTS OF ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: COMPARISON BETWEEN CLOPIDOGREL AND PRASUGREL PATIENTS IN A UNITED STATES HOSPITAL DATABASE

 

Bae JP1, Ernst FR2, Lipkin C2, Zhao Z1, Faries DE1, Moretz C2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Premier Healthcare Alliance, Charlotte, NC, USA

PCV26

COST ANALYSIS OF TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME IN RUSSIA

 

Pyadushkina EA1, Gerasimova KV2, Avxentyeva M1, Krysanov I1
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2The First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia

PCV27

PHARMACOECONOMIC EVALUATION OF NEUROPROTECTIVE THERAPY OF PATIENTS WITH ACUTE ISCHEMIC STROKE IN UKRAINE

 

Mishchenko O1, Iakovlieva L1, Adonkina V1, Chinush I1, Matyashova N2
1National University of Pharmacy, Kharkiv, Ukraine, 2National University of Pharmacy, Kharkiv, Ukraine

PCV28

2-YEAR INCIDENCE OF STROKE AND HEMORRHAGES HOSPITALIZATIONS AND COSTS WITHIN ATRIAL FIBRILLATION PATIENTS IN FRANCE

 

Cotté FE1, Chaize G2, Kachaner I3, Gaudin AF4, Vainchtock A5, Durand-Zaleski I6
1Bristol-Myers Squibb, Rueil-Malmaison , France, 2HEVA, Lyon, France, 3Pfizer, Paris, France, 4Bristol-Myers Squibb, Rueil Malmaison, France, 5HEVA, LYON, France, 6Hôpital Henri Mondor, Créteil, France

PCV29

HEALTH CARE RESOURCE UTILIZATION AND COSTS OF CARDIOEMBOLIC STROKE IN THE REGION OF MADRID, SPAIN: PRELIMINARY RESULTS OF CODICE STUDY

 

de Andres F1, Vivancos J2, Barriga FJ3, Diaz F4, Izquierdo L5, Ortega MA6, Castillo L3, Ximenez-Carrillo A2, Martin MP4, Gomez-Escalonilla CI5, Torres C1, de Salas-Cansado M7, Casado MA1, Soto J8, Gil-Nuñez A4
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, Madrid, Spain, 2Hospital Universitario de La Princesa, Madrid, Madrid, Spain, 3Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain, 4Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain, 5Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, 6Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain, 7Pfizer Spain, Alcobendas, Madrid, Spain, 8Pfizer España, Alcobendas/Madrid, Spain

PCV30

ASSESSMENT OF THE HOSPITAL COSTS OF MITRAL REGURGITATION (MR) PATIENTS, A FRENCH NATIONAL HOSPITAL DATABASE ANALYSIS

 

Cros S1, Levesque K2, Bufi L3, Caranhac G4, Gotlieb L3
1Abbott Vascular International BVBA, Diegem, Belgium, 2Abbott Vascular, Rungis Cedex, NT, Canada, 3Abbott Vascular, DIEGEM, Belgium, 4HOX-COM Analytiques, Vincennes, France

PCV31

COST OF CARDIOVASCULAR DISEASES IN SERBIA

 

Lakić D1, Tasic L1, Kos M2, Odalović M1, Tadić I1
1University of Belgrade – Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 2Faculty of Pharmacy, University of Ljubljana, Ljubljana, Serbia and Montenegro

PCV32

THE COST OF DIABETES COMPLICATIONS IN BELGIUM

 

Lamotte M, Chevalier P
IMS Health, Vilvoorde, Belgium

PCV33

ECONOMIC BURDEN OF CARDIOVASCULAR DISEASES IN RUSSIAN FEDERATION

 

Kontsevaya A, Kalinina A
National Research Center for Preventive Medicine, Moscow, Russia

PCV34

THE ECONOMIC COST OF ACUTE CORONARY SYNDROME IN TURKEY

 

Cakir B1, Caliskan Z1, Ergun H2, Erol C2, Gumusel B1, Tokgozoglu L1, Dayioglu M3
1Hacettepe University, Ankara, Turkey, 2Ankara University, Ankara, Turkey, 3Eli Lilly and Company, Istanbul, Turkey

PCV35

COSTS OF TREATING CARDIOVASCULAR DISEASES IN GERMANY: A SYSTEMATIC LITERATURE REVIEW

 

Xu W1, Hensen M1, Steinle T2, Pelosi C3
1Pharmerit International, Rotterdam, The Netherlands, 2Amgen (Europe) GmbH, München, Germany, 3Amgen, Zug, Switzerland

PCV36

INCREASING COSTS FOR GERMAN SOCIAL HEALTH INSURANCE (SHI) FUNDS BY ABANDONMENT OF PENTAERITHRITYLTETRANITRAT (PETN) FOR PATIENTS WITH CORONARY HEART DISEASE (CHD)? – A COST ANALYSIS BASED ON SICK FUND DATA

 

Pirk O1, Klingmann I2, Schneider HT3, Stalleicken D4, Warmuth W5
1Olaf Pirk Consult, Nuremberg, Germany, 2Pharmaplex bvba, Wezembeek-Oppem, Belgium, 3Med. Fakultät Universität Bonn, München , Germany, 4Actavis Deutschland GmbH & Co. KG, München, Germany, 5Gesundheitsforen Leipzig GmbH, Leipzig, Germany

PCV37

VIP STUDY: INCREMENTAL COST DURING HOSPITALIZATION AFTER TOTAL KNEE AND HIP ARTHROPLASTY IN BRAZILIAN HEALTH CARE SERVICES

 

Mainine S1, Nita ME2, Scheinberg M3, Vasconcelos P4, Guerra R5, Takemoto M6, Fujii RK7, Mould JF8, Loures-Vale AA9, Presa J10, Rached R2, Juarez Garcia A11, Donato BMK12, Rahal E2
1Hospital Estadual Mario Covas da Faculdade de Medicina do ABC, Santo Andre, Brazil, 2Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 3Hospital AACD, Sao Paulo, Brazil, 4Hospital Santa Cruz, Sao Paulo, Brazil, 5ANOVA, Rio Janeiro, Brazil, 6ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 7Pfizer, Inc., São Paulo, São Paulo, Brazil, 8Pfizer, New York, NY, USA, 9Pfizer, Sao Paulo, Brazil, 10Pfizer Parmaceutics Inc., São Paulo, São Paulo, Brazil, 11Bristol-Myers Squibb Mexico City, Mexico DF, Mexico, Mexico, 12Bristol-Myers Squibb Company, Wallingford, CT, USA

PCV38

ECONOMIC EVALUATION OF ANTICOAGULANT STRATEGIES IN INTERVENTIONAL TREATMENT OF ACUTE MYOCARDIAL INFARCTION

 

Reinöhl J1, Neubauer A2, Ahrens I1, Neumann FJ3, Zeymer U4, Neubauer G2, Bode C1, Zehender M1
1Universitätsklinik Freiburg, Freiburg, Germany, 2Institut für Gesundheitsökonomik München, München, Germany, 3Herzzentrum Bad Krozingen, Bad Krozingen, Germany, 4Herzzentrum Ludwigshafen, Ludwigshafen, Germany

PCV39

COST ASSESSMENT OF DRUGS FOR VENOUS THROMBOEMBOLISM PREVENTION AFTER HIP OR KNEE REPLACEMENT IN MEXICAN POPULATION

 

Contreras I1, Torres-Gonzalez R1, Ocegueda-Sosa MA2, Hernandez-Cuevas V3, Mendoza-Lemus OF4, Vilchez-Cavazos F4
1Instituto Mexicano del Seguro Social, México City, Mexico, 2Hospital Regional No. 2 Instituto Mexicano del Seguro Social, Mexico, Mexico, 3Hospital Regional No. 2 Instituto Mexicano del Seguro Social, Mexico, Mexico, Mexico, 4Hospital universitario , Monterrey, Mexico

PCV40

PHARMACOTHERAPY COST OF PATIENTS WITH HYPERTENSION IN BULGARIA

 

Marinov L, Kamusheva M, Nikolova I, Petkova V, Petrova G
Medical University, Faculty of Pharmacy, Sofia, Bulgaria

PCV41

MODEL SENSITIVITY ANALYSIS OF VENOUS THROMBOEMBOLISM PREVENTION AFTER TOTAL KNEE REPLACEMENT

 

Vorobiev P1, Krasnova L1, Shustov A1, Bashlakova E2
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Moscow State Medical University named after I.M. Sechenov, Moscow, Russia

PCV42

MODEL SENSITIVITY ANALYSIS OF VENOUS THROMBOEMBOLISM PREVENTION AFTER TOTAL HIP REPLACEMENT

 

Vorobiev P1, Krasnova L1, Shustov A1, Bashlakova E2
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2The First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia

PCV43

FAIR COST-BENEFIT EVALUATION OF HEALTH CARE: A CASE STUDY OF BLOOD PRESSURE LOWERING DRUGS IN FRANCE

 

Dormont B1, Fleurbaey M2, Luchini S3, Samson AL1, Schokkaert E4, Thébaut C5, Van de Voorde C6
1Dauphine University, Paris, France, 2Princeton University, Princeton, NJ, USA, 3GREQAM, Marseille, France, 4Katholieken Universitat Leuven, Leuven, Belgium, 5Haute Autorité de Santé, Saint-Denis, France, 6Katholieke Universitat Leuven, Leuven, Belgium

PCV44

ECONOMIC EVALUATION OF A SINGLE-PILL TRIPLE COMBINATION WITH VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AGAINST ITS DUAL COMPONENTS IN GREECE. THE GENERIC SUBSTITUTION CASE

 

Stafylas P1, Kourlaba G2, Georgiopoulos D3, Hatzikou M3, Maniadakis N2
1AHEPA University Hospital, Kalamaria, Greece, 2National School of Public Health, Athens, Greece, 3Novartis Hellas, Metamorfosis, Greece

PCV45

LONG TERM COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES FROM A TURKISH HEALTH CARE PERSPECTIVE BASED ON DATA FROM THE PLATO TRIAL

 

Abaci A1, Bozkurt E2, Mellstrom C3, Caglayan B4
1Gazi University, Ankara, Turkey, 2Atatürk Educational Hospital, ANKARA, Turkey, 3AstraZeneca, Mölndal, Sweden, 4AstraZeneca Turkey, Istanbul, Turkey

PCV46

THE PHARMACOECOMOMIC ANALYSIS OF ILOPROST IN CRITICAL LIMB ISCHEMIA

 

Avxentyeva M1, Krysanov I1, Chupin A2
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Clinical Hospital N 83, Moscow, Russia

PCV47

ECONOMIC EVALUATION OF DABIGATRAN FOR STROKE PREVENTION AMONG PATIENTS WITH ATRIAL FIBRILLATION IN THE NETHERLANDS

 

Le HH1, Pechlivanoglou P1, Engelfriet PM2, Postma MJ1, Redekop WK3
1University of Groningen, Groningen, The Netherlands, 2National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The Netherlands

PCV48

SYSTEMATIC REVIEW OF COST-EFFECTIVENESS MODELS FOR PHARMACOLOGIC STROKE PREVENTION IN ATRIAL FIBRILLATION

 

Limone B1, Baker WL2, Roberts M1, Coleman CI3
1Hartford Hospital, Hartford, CT, USA, 2University of Connecticut, Hartford, CT, USA, 3University of Connecticut, Storrs, CT, USA

PCV49

ECONOMIC EVALUATION OF RIVAROXABAN IN STROKE PREVENTION AMONG PATIENTS WITH ATRIAL FIBRILLATION IN GREECE

 

Kourlaba G1, Maniadakis N1, Andrikopoulos G2, Vardas P3, Llyod A4, Asukai Y4, Evers T5
1National School of Public Health, Athens, Greece, 2Henry Dunant Hospital, Athens, Greece, 3University of Crete, Heraklion, Crete , Greece, 4IMS Health, London, UK, 5Bayer Schering Pharma AG, Wuppertal, Germany

PCV50

COST-EFFECTIVENESS ANALYSIS OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR VERSUS CLOPIDOGREL IN HONG KONG: A MARKOV ANALYTIC MODEL

 

Lee VWY1, Chow IHI1, Yan BP2, Yu CM1, Lam YY1
1The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, 2Prince of Wales Hospital & Monash University, Hong Kong, Hong Kong, China

PCV51

COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN ADULT PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION WITH ONE OR MORE RISK FACTORS – A UK PERSPECTIVE

 

Asukai Y1, Duran A1, Lloyd A1, McLeod EJ1, Evers T2, Broughton J3
1IMS Health, London, UK, 2Bayer HealthCare AG, Wuppertal, Germany, 3Bayer Plc, Newbury, UK

PCV52

COST-EFFECTIVENESS OF ADDING EZETIMIBE TO ATORVASTATIN THERAPY IN PORTUGAL

 

Laires P1, Tun-Ying H2, Ambegaonkar BM3, Davies GM4
1Merck, Sharp & Dohme, Oeiras, Portugal, 2Merck, Sharp & Dohme, WHITEHOUSE STATION, NJ, USA, 3Merck & Co. Inc., Whitehouse Station, NJ, USA, 4Merck & Co. Inc., Upper Gwynedd, PA, USA

PCV53

ECONOMIC EVALUATION OF A SINGLE PILL TRIPLE ANTIHYPERTENSIVE THERAPY WITH VALSARTAN, AMLODIPINE, AND HYDROCHLOROTHIAZIDE AGAINST ITS DUAL COMPONENTS IN GREECE

 

Stafylas P1, Kourlaba G2, Hatzikou M3, Georgiopoulos D3, Maniadakis N2
1AHEPA University Hospital, Kalamaria, Greece, 2National School of Public Health, Athens, Greece, 3Novartis Hellas, Metamorfosis, Greece

PCV54

ECONOMIC EVALUATION OF RIVAROXABAN IN THE TREATMENT OF DEEP VEIN THROMBOSIS IN GREECE

 

Kourlaba G1, Maniadakis N1, Giannoukas A2, Katsamouris A3, Katsenis K4, Lazarides M5, Matsagas M6, Lowin J7, McLeod EJ8, Bamber L9
1National School of Public Health, Athens, Greece, 2University of Thessaly, Larissa, Greece, 3University of Crete, Heraklion, Crete, Greece, 4University of Athens, Athens, Greece, 5Democritus University, Thrace, Greece, 6University of Ioannina, Ioannina, Greece, 7IMS Health, London , UK, 8IMS Health, London, UK, 9Bayer Pharma AG, Wuppertal, Germany

PCV55

A COST-EFFECTIVENESS ANALYSIS OF CORALAN® (IVABRADINE) PLUS STANDARD CARE VERSUS STANDARD CARE ALONE IN CHRONIC HEART FAILURE

 

Ergene O1, Oto A2, Cavusoglu Y3, Aydogdu S4, Ozdemir O5, Tan M6
1Izmir Ataturk Training and Research Hospital, Izmir, Turkey, 2Hacettepe University School of Medicine, Ankara, Turkey, 3Osmangazi University Medical School, ESKISEHIR, Turkey, 4Ankara Yuksek Ihtisas Hospital, ANKARA, Turkey, 5Yorum Consulting Co. Ltd., Istanbul, Turkey, 6Servier Ilac ve Arastirma A.S., Istanbul, Turkey

PCV56

COST EFFECTIVENESS OF ADDING EZETIMIBE TO ATORVASTATIN THERAPY IN PATIENTS NOT AT LDL CHOLESTEROL TREATMENT GOAL IN BRAZIL

 

Araujo GT1, Fonseca M2, Etto H3, Davies GM4, Hsu TY5
1Axia.Bio Consulting, Sao Paulo, Sao Paulo, Brazil, 2Federal University of São Paulo / Axia.Bio Consulting, São Paulo, Brazil, 3Axia.Bio, Sao Paolo, Brazil, 4Merck & Co. Inc., Upper Gwynedd, PA, USA, 5Merck, Sharp & Dohme, WHITEHOUSE STATION, NJ, USA

PCV57

COST-EFFECTIVENESS OF IVABRADINE IN THAI HEART FAILURE PATIENT

 

Vichairuangthum K1, Yodla P1, Sakthong P2
1Bangkok Metropolitan Administration Medical College and Vajira Hospital, Bangkok, Thailand, 2Chulalongkorn University, Bangkok, Thailand

PCV58

THE COST EFFECTIVENESS OF AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE SINGLE PILL COMBINATION IN TURKEY

 

Guclu H, Berktas M, Sencan N, Ozbay L
Yeditepe University, Istanbul, Turkey

PCV59

WHERE DID THE TIME GO?: TEMPORAL UNCERTAINTY IN COST-EFFECTIVENESS DECISION MODELS

 

Mahon R1, Manca A2, Palmer S1
1University of York, York, North Yorkshire, UK, 2University of York, Heslington, York, UK

PCV60

COST EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN THE TURKISH HEALTH CARE SETTING

 

Kececioglu S, Ulus P, Cukadar F
Boehringer Ingelheim Turkey, ISTANBUL, TURKEY, Turkey

PCV61

PHARMACOECONOMIC EVALUATION OF OLMESARTAN, LOSARTAN AND VALSARTAN IN TREATMENT OF ESSENTIAL ARTERIAL HYPERTENSION

 

Gorokhova SG, Ryazhenov VV
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCV62

CLINICAL AND ECONOMIC ANALYSIS OF THE EFFECTIVENESS OF ANTIHYPOXIA SUBSTANCE POLYDIHYDROXYPHENYLENETHIOSULFONATE SODIUM (HYPOXENUM) IN THE COMPLEX ANGINA PECTORIS TREATMENT

 

Vorobiev P, Luneva A
Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia

PCV63

WITHDRAWN

 

 

PCV64

COST-EFFECTIVENESS OF TICAGRELOR IN THE MANAGEMENT OF ACUTE CORONARY SYNDROMES IN BELGIUM

 

Chevalier P1, Lamotte M1, Petit C2
1IMS Health, Vilvoorde, Belgium, 2AstraZeneca, Brussels, Belgium

PCV65

A HEALTH ECONOMIC EVALUATION OF OMEGA-3 ACID ETHYL ESTERS 90 IN THE SECONDARY PREVENTION POST- MI

 

Gerlier L1, Vellopoulou K1, Lamotte M1, Lacey L2, Einroos A3, Carr E4
1IMS Health, Vilvoorde, Belgium, 2Lacey Solutions Ltd, Skerries, Ireland, 3Abbott Laboratories, Tallinn, Estonia, 4Abbott Laboratories, Allschwil, Switzerland

PCV66

PHARMACOECONOMIC ANALYSIS OF AZILSARTAN MEDOXOMIL IN PATIENTS WITH ARTERIAL HYPERTENSION: COMPARISON WITH VALSARTAN, TELMISARTAN, LOSARTAN AND IRBESARTAN IN THE MEXICAN CONTEXT

 

Zamora Muciño-Arroyo AJ1, Gay-Molina JG2, Chiu-Ugalde J3, Figueroa-Rodriguez A3, Arellano Plancarte A3, López-Alvarenga JC4, Sánchez-Kobashi R2, Vargas JA3
1Hospital Cardiológica, Aguascalientes, Ags., Mexico, 2Tecnología e Informática para la Salud, S.A. de C.V., Mexico City, Mexico, 3Nycomed: A Takeda Company, Naucalpan, Edo.
México, Mexico, 4Hospital General de México O.D., Mexico City, Mexico

PCV67

MIND THE GAP! GEOGRAPHIC TRANSFERABILITY OF ECONOMIC EVALUATION IN HEALTH

 

Boehler CEH, Buxton M, Lord J
HERG, Brunel University, Uxbridge, UK

PCV68

ECONOMIC EVALUATION OF INITIATION WITH ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN SPAIN

 

Villa G1, Escribano P2, Gil J3, Roman A4, Morano R1
1GlaxoSmithKline, Madrid, Spain, 2Hospital Universitario 12 de Octubre, Madrid, Spain, 3Hospital General Universitario de Alicante, Alicante, Spain, 4Hospital Universitari Valle d'Hebron, Barcelona, Spain

PCV69

ECONOMIC EVALUATION OF THROMBO INCODE, A GENETIC PLATFORM FOR THE ASSESSMENT OF VENOUS THROMBOEMBOLISM (VTE) RISK IN PATIENTS WITH A PATTERN OF VTE OR A CONDITION THAT SUGGESTS A HEREDITARY COMPONENT

 

Marrugat J1, Elosúa R1, Coca A2, de la Figuera M3, Rubio-Terrés C4, Rubio-Rodríguez D5, Ramírez de Arellano A6, Boldeanu A6, Puig-Gilberte J7, Salas E7
1IMIM-Hospital del Mar, Barcelona, Spain, 2Hospital Clínic, Barcelona, Spain, 3CAP Cerdenya, Barcelona, Spain, 4HealthValue, Madrid, Spain, 5Health Value, Madrid, Spain, 6FERRER-inCode, Barcelona, Spain, 7GENDIAG, Barcelona, Spain

PCV70

COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN SMOKERS WITH CARDIOVASCULAR DISEASE IN THE NETHERLANDS

 

Majer IM1, Rozenbaum MH2, Verheggen B1
1Pharmerit International, Rotterdam, Zuid-Holland, The Netherlands, 2Pfizer Nederland, Capelle aan den Ijseel, Zuid-Holland, The Netherlands

PCV71

ECONOMIC EVALUATION OF LIPID LOWERING THERAPY IN THE SECONDARY PREVENTION SETTING IN THE PHILIPPINES

 

Mendoza VL1, Tumanan-Mendoza BA2
1De La Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines, 2University of the Philippines College of Medicine, Manila, Philippines

PCV72

COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ACENOCUMAROL IN THE STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILATION IN THE SPANISH SETTING

 

Restovic G1, Carcedo D1, McLeod EJ2, Guillermin ALG3, Evers T4
1Bayer Pharma, Barcelona-Spain, Barcelona, Barcelona, Spain, 2IMS Health, London, UK, 3IMS Health, London , UK, 4Bayer Schering Pharma AG, Wuppertal, Germany

PCV73

PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION: COST-UTILITY ANALYSIS OF RIVAROXABAN VERSUS WARFARIN IN SLOVAKIA

 

Psenkova M1, Lukac M2, Mackovicova S3, Stachova M2, Bielik J4, Pietsch GA5, Asukai Y6, Lloyd A6, Evers T7
1Pharm-In, Bratislava, Slovak Republic, 2Bayer, Bratislava, Slovak Republic, 3Pharm-In, spol. s r.o., Bratislava, Slovak Republic, 4Trencin University, Trencin, Slovak Republic, 5Bayer Schering Pharma AG, Wupertal, GA, Germany, 6IMS Health, London, UK, 7Bayer Schering Pharma AG, Wuppertal, Germany

PCV74

ECONOMIC EVALUATION OF CARDIO INCODE, A GENETIC PLATFORM FOR THE ASSESSMENT OF ISCHEMIC HEART DISEASE RISK

 

Marrugat J1, Elosúa R1, Coca A2, de la Figuera M3, Rubio-Terrés C4, Rubio-Rodríguez D5, Ramírez de Arellano A6, Boldeanu A6, Puig-Gilberte J7, Salas E7
1IMIM-Hospital del Mar, Barcelona, Spain, 2Hospital Clínic, Barcelona, Spain, 3CAP Cerdenya, Barcelona, Spain, 4HealthValue, Madrid, Spain, 5Health Value, Madrid, Spain, 6FERRER-inCode, Barcelona, Spain, 7GENDIAG, Barcelona, Spain

PCV75

COMPLEMENTING DATA FOR RARE DISEASES - COMPARING DATA FROM NATIONAL REGISTRIES TO A EUROPEAN CHART ABSTRACTION STUDY FOR PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

 

Schweikert B1, Dalén J2, Berg J2, Eriksson M3, Sikirica M4
1OptumInsight, Munich, Germany, 2OptumInsight, Stockholm, Sweden, 3Bayer AB, Solna, Sweden, 4Bayer Pharma AG, Berlin, Germany

PCV76

STANDARD COSTS AND RESOURCES ALLOCATION IN ATTAINMENT OF TARGET LIPID LEVELS AMONG EXPERIENCED STATIN USERS: RESULTS FROM THE STAR STUDY (STATINS TARGET ASSESSMENT IN REAL PRACTICE)

 

Degli Esposti L, Buda S, Sangiorgi D, Degli Esposti E
CliCon Srl, Ravenna, Italy

PCV77

ANALYSIS OF HOSPITAL-SPECIFIC DRG PAYMENTS FOR STROKE ACCORDING TO UNITED STATES MEDICARE PERSPECTIVE

 

Blein C, Marty R, Roze S
HEVA, Lyon, France

CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PCV78

WITHDRAWN

 

 

PCV79

COMPLIANCE WITH WARFARIN THERAPY BY AUSTRALIAN PATIENTS WITH ATRIAL FIBRILLATION

 

Ortiz MS1, Calcino G2, Germanos P3
1University of NSW, Darlinghurst, NSW, Australia, 2HI Connections, Woden, ACT, Australia, 3Boehringer Ingelheim Pty Limited, North Ryde, NSW, Australia

PCV80

A RETROSPECTIVE STUDY OF COMPARING COMPLIANCE AND PERSISTENCE OF FREE COMBINATION ANTIHYPERTENSIVE THERAPY VERSUS SINGLE-PILL COMBINATION: KOREAN CASE

 

Min J1, Min K2, Hong J3, Kim EG3, Shin K4, Yang BM3
1Institute of Health and Environment, Seoul National University, Seoul, South Korea, 2Ajou University School of Medicine, Suwon, South Korea, 3Seoul National University, Seoul, South Korea, 4Novartis Korea, Seoul, Seoul, South Korea

PCV81

AWARENESS OF SERIOUS CONSEQUENCES OF NON-COMPLIANCE AND SELF-REPORTED ADHERENCE TO ANTIPALTELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION

 

Lee N1, Yu CM2, Lee VW2, Yan BP3
1University of Sheffield, Sheffield, UK, 2The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, 3Prince of Wales Hospital & Monash University, Hong Kong, Hong Kong, China

PCV82

OBSERVATIONAL STUDY EVALUATING THE LEVEL OF COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS IN THE GREEK POPULATION

 

Georgiopoulos D1, Hatzikou M1, Demousis F2, Sakalides C3
1Novartis Hellas, Metamorfosis, Greece, 2Foundation for Economic and Industrial Research (IOBE), Athens, Greece, 3Iatriko Kentro Palaiou Falirou, N. Smyrni, Greece

PCV83

ADHERENCE TO ANTIHYPERTENSIVE AGENTS AFTER A RECENT ISCHEMIC STROKE AND RISK OF CARDIOVASCULAR OUTCOMES : A POPULATION BASED STUDY

 

Perreault S1, Yu AYX2, Côté R2, Dragomir A3, White-Guay B3, Dumas S3
1Université de Montréal, Montréal, QC, Canada, 2McGill University, Montreal, QC, Canada, 3University of Montreal, Montreal, QC, Canada

PCV84

MISDIAGNOSIS AND MISTREATMENT OF ACE-INHIBITOR INDUCED COUGH DECREASES THERAPY COMPLIANCE

 

Vegter S, de Boer P, van Dijk KW, Visser ST, de Jong-van den Berg LT
University of Groningen, Groningen, The Netherlands

PCV85

PERSISTENCE OF PATIENTS TREATED HYPERTENSIVE MEDICATION IN PBM WITH DIFFERENT PERCENTAGES OF FINANCIAL SUBSIDY

 

Apendino LR1, Paloni EDMP2, Ferreira CN2, Santana CFSD3, Salles GRD4
1Orizon, SAO PAULO, Brazil, 2ORIZON - Companhia Brasileira de Gestão de Serviços, Sao Paulo, Sao Paulo, Brazil, 3Orizon, Sao Paulo, SP, Brazil, 4Orizon, Sao Paulo, Sao Paulo, Brazil

PCV86

THE BURDEN OF NON-ADHERENT PRESCRIPTION COST CUTTING AMONG DIAGNOSED HYPERTENSION PATIENTS IN RUSSIA

 

Gupta S1, Vietri J1, DiBonaventura MD2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA

PCV87

FACTORS RELATED TO NON-ADHERENCE AND SATISFACTION FOR HYPERTENSION MEDICATIONS: RESULTS FROM A NOVEL PATIENT REGISTRY

 

Kamble S1, Cascade E2, Gemmen E1
1Quintiles Outcome, Rockville, MD, USA, 2Quintiles, Inc., Rockville, MD, USA

PCV88

VENOUS THROMBOEMBOLISM: A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY MULTI-ATTRIBUTE UTILITY VALUES FOR USE IN ECONOMIC MODELS

 

Sungher DK1, Folkerts K2, Mcdonald H3, Diamantopoulos A1
1Symmetron Limited, Elstree, Herts, UK, 2Bayer Schering Pharma AG, Wuppertal, Germany, 3Bayer Inc., Toronto, ON, Canada

PCV89

EXPERIENCE SAMPLING TO OBTAIN HEALTH STATE VALUATIONS

 

Maes IH1, Anteunis LJ1, Delespaul PA2, White MP3, Joore MA4
1Maastricht University Medical Centre, Maastricht, The Netherlands, 2Maastricht University, Maastricht, The Netherlands, 3University of Plymouth, Plymouth, UK, 4MUMC, Maastricht, The Netherlands

PCV90

A NOVEL CONCEPTUAL MODEL OF CAREGIVER BURDEN IN CHRONIC HEART FAILURE: A QUALITATIVE STUDY

 

Blackburn S1, Humphrey L1, Maguire L1, Deschaseaux C2, Stromberg A3
1Adelphi Values, Bollington, Cheshire, UK, 2Novartis Pharma, Basel, Switzerland, 3Linköping University, Linkoping, Sweden

PCV91

THE IMPACT OF ATRIAL FIBRILATION SYMPTOMS IN THE HEALTH RELATED QUALITY OF LIFE IN SPANISH POPULATION (ULISES STUDY)

 

Arribas F1, Montull E2, LLobet X2, Perulero N3, Badia X4
1Hospital Universitario 12 de Octubre, MADRID, Spain, 2SANOFI AVENTIS S.A., BARCELONA, Spain, 3IMS Health, S.A., Barcelona, Spain, 4IMS Health, Barcelona, Spain

PCV92

COMPARISON OF THE PSYCHOMETRIC PROPERTIES OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) AND THE SF-36 IN PATIENTS WITH PULMONARY HYPERTENSION

 

Twiss J1, Ganderton L2, Jenkins S3, Ben-L'amri M1, Gain K4, Fowler R3, Gabbay E3, McKenna S1
1Galen Research Ltd, Manchester, UK, 2Discipline of Physiotherapy, Sydney, Australia, 3Curtin University, Perth, Australia, 4The University of Western Australia, Crawley, Australia

PCV93

STUDY OF THE USE OF QUALITY OF LIFE QUESTIONNAIRES IN CARDIAC DISEASES IN POLAND

 

Sieluk J1, Zawodnik S2, Hermanowski T3
1Medical University of Warsaw, Warsaw, Masovian, Poland, 2Medical University of Warsaw, Warsaw, Poland, 3Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

PCV94

THE INFLUENCE OF DISEASE-SPECIFIC SYMPTOMS ON THE HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ATRIAL FIBRILLATION

 

Wilke T1, Müller S2, Bauersachs R3, Breithardt G4
1Hochschule Wismar, Wismar, Germany, 2IPAM, Wismar, Germany, 3Klinikum Darmstadt GmbH, Darmstadt, Germany, 4University Clinic Muenster, Muenster, Germany

PCV95

THE PATIENT'S EXPERIENCE OF NUISANCE BLEEDING AND BRUISING WHILE ON ANTIPLATELET MEDICATIONS FOR ACS

 

Gwaltney C1, Slagle A2, Martin ML3, Mollon P4
1Invivodata, Inc., Westerly, RI, USA, 2FDA/CDER/OND, Silver Spring, MD, USA, 3Health Research Associates, Inc., Seattle, WA, USA, 4Novartis Pharma AG, Basel, Switzerland

PCV96

RELATIONSHIP BETWEEN INFLAMMATION AND PATIENT FUNCTIONING IN CARDIOVASCULAR DISEASE: A REVIEW OF THE LITERATURE

 

Gwaltney C1, St. Charles M2, Mollon P3, Falvey H3
1Invivodata, Inc., Westerly, RI, USA, 2Invivodata, Inc., Pittsburgh, PA, USA, 3Novartis Pharma AG, Basel, Switzerland

PCV97

BURDEN OF DYSPEPSIA AMONG PATIENTS WITH ATRIAL FIBRILLATION IN JAPAN

 

Kinoshita Y1, DiBonaventura MD2, Wang ECY3, Rossi B4, Iwamoto K4, Stankus A5, Briere JB6
1Shimane University School of Medicine, Izumo, Shimane , Japan, 2Kantar Health, New York, NY, USA, 3Bayer Yakuhin, Ltd., Tokyo, Japan, 4Bayer Yakuhin, Ltd., Kita-ku, Osaka, Japan, 5Kantar Health, Princeton, NJ, USA, 6Bayer Yakuhin, Ltd., Chiyoda-ku, Tokyo, Japan

PCV98

HEALTH RELATED QUALITY OF LIFE AND AGE IN HYPERTENSIVE PATIENTS: SELF-PERCEPTION AND EVALUATION BY PROFESSIONALS. THE EQUALITY STUDY

 

Font B1, Lahoz R1, Salazar J1, Roca-Cusachs A2, Abellán J3, Ruíz D2
1Novartis Farmaceutica, Barcelona, Spain, 2Santa Creu i Sant Pau Hospital.
Universidad Autónoma de Barcelona, Barcelona, Spain, 3Universidad Católica de Murcia, Guadalupe (Murcia), Spain

PCV99

EQ-5D UTILITIES IN PATIENTS HOSPITALISED WITH HEART FAILURE IN CANARY ISLANDS

 

García-Pérez L1, Linertová R1, Pinilla-Domínguez P1, Dávila-Ramos M2, Copca-Álvarez A2, Ruiz-Hernández JJ3, Díaz-Escofet M3, Escobar A4
1Fundación Canaria de Investigación y Salud (FUNCIS), Las Palmas de Gran Canaria, Spain, 2Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, 3Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, 4Basurto University Hospital (Osakidetza), Bilbao, Bizkaia, Spain

PCV100

COMPARISON OF HEALTH-RELATED WORK IMPAIRMENT IN RUSSIAN PATIENTS WITH US AND 5EU

 

Gross HJ1, Isherwood G2, Vietri J1
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, Epsom, Surrey, UK

PCV101

JAPANESE PATIENTS AND PHYSICIANS PREFERENCES FOR ANTICOAGULANTS USE IN ATRIAL FIBRILLATION - RESULTS FROM A CONJOINT-ANALYSIS STUDY

 

Okumura K1, Inoue H2, Yasaka M3, Gonzalez JM4, Hauber AB4, Iwamoto K5, Wang ECY6, Rossi B5, Levitan B7, Yuan Z8, Briere JB9
1Hirosaki University Graduate School of Medicine, Hirosaki, Japan, 2University of Toyama School of Medicine, Toyama, Japan, 3Kyushu Medical Center, Fukuoka, Japan, 4RTI Health Solutions, Research Triangle Park, NC, USA, 5Bayer Yakuhin, Ltd., Kita-ku, Osaka, Japan, 6Bayer Yakuhin, Ltd., Tokyo, Japan, 7Johnson & Johnson PRD, Titusville, NJ, USA, 8Janssen, Titusville, NJ, USA, 9Bayer Yakuhin, Ltd., Chiyoda-ku, Tokyo, Japan

PCV102

CHARACTERISTICS INFLUENCING JAPANESE ATRIAL FIBRILLATION PATIENTS PREFERENCES FOR ANTICOAGULANTS USE

 

Okumura K1, Inoue H2, Yasaka M3, Gonzalez JM4, Hauber AB4, Iwamoto K5, Wang ECY6, Rossi B5, Briere JB7
1Hirosaki University Graduate School of Medicine, Hirosaki, Japan, 2University of Toyama School of Medicine, Toyama, Japan, 3Kyushu Medical Center, Fukuoka, Japan, 4RTI Health Solutions, Research Triangle Park, NC, USA, 5Bayer Yakuhin, Ltd., Kita-ku, Osaka, Japan, 6Bayer Yakuhin, Ltd., Tokyo, Japan, 7Bayer Yakuhin, Ltd., Chiyoda-ku, Tokyo, Japan

PCV103

DEVELOPMENT OF A NEW QUESTIONNAIRE TO MEASURE SATISFACTION WITH MEDICAL CARE IN PATIENTS WITH ATRIAL FIBRILLATION (SAFUCA)

 

Ruiz MA1, González-Porras JR2, Aranguren JL3, Tuñón JL4, Bover R5, de Salas-Cansado M6, Pardo A1, Soto J7
1Universidad Autonoma de Madrid, Madrid, Spain, 2Universitary Hospital of Salamanca, Salamanca, Spain, 3Clínica Madrid, Madrid, Fuenlabrada, Spain, 4Universidad Autónoma de Madrid, Madrid, Spain, 5Hospital Clínico San Carlos, Madrid, Spain, 6Pfizer Spain, Alcobendas, Madrid, Spain, 7Pfizer España, Alcobendas/Madrid, Spain

CARDIOVASCULAR DISORDERS – Health Care Use & Policy Studies

PCV104

RELATIONSHIP BETWEEN COMORBIDITIES, BLOOD PRESSURE CONTROL AND THERAPEUTIC SCHEMES IN REAL-LIFE SETTING HYPERTENSIVE PATIENTS

 

Ansolabehere X, Grandfils N, Morlet Vigier D
IMS Health, Puteaux, France

PCV105

THE IMPORTANCE OF A DEFINITION: COST IMPLICATIONS FOR THE UK OF ALTERNATIVE DEFINITIONS OF HYPERCHOLESTEROLAEMIA

 

Jameson K1, D'Oca K1, Amber V2, Quoraishi SH1, O'Regan C1
1MSD Ltd., Hoddesdon, UK, 2MSD Ltd., Hertfordshire, UK

PCV106

AFFORDABILITY OF ANTI-HYPERTENSIVE MEDICATION IN EGYPT UNDER CURRENT REIMBURSEMENT SYSTEMS

 

Abbas Y1, Abaza S2, El-Shalakny A3, Keskinaslan A4
1Heller School for Social Policy & Management, Brandeis University, Waltham, MA, USA, 2Novartis Pharma S.A.E., Cairo, Cairo, Egypt, 3Ministry of Health in Egypt, Cairo, Cairo, Egypt, 4Novartis Pharma AG, Basel, Basel, Switzerland

PCV107

GENERIC ATORVASTATIN, THE BELGIAN STATIN MARKET AND THE COST-EFFECTIVENESS OF STATIN THERAPY

 

Simoens S1, Sinnaeve P2
1Katholieke Universiteit Leuven, Leuven, Vlaams Brabant, Belgium, 2University Hospitals Leuven, Leuven, Belgium

PCV108

ANALYSIS OF OUTPATIENT UTILIZATION AND COSTS OF ANTITHROMBOTIC DRUGS IN POLAND – IMPLICATIONS FOR PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICY

 

Bochenek T1, Nizankowski R2
1Jagiellonian University, Collegium Medicum, Krakow, Poland, 2Jagiellonian University, Krakow, Poland

PCV109

ANTITHROMBOTIC THERAPY PRESCRIPTION AND PERSISTENCE IN PATIENTS WITH ATRIAL FIBRILLATION IN FRANCE AND SPAIN

 

Huguet M1, Shakespeare A2, Haug HM3, Miadi-Fargier H3, Restovic G4, Rafols C4, Kempf C1
1Cegedim Strategic Data, Boulogne-Billancourt, Île-de-France, France, 2Bayer Plc, Uxbridge, Greater London, UK, 3Bayer Santé S.A.S., Loos, Nord, France, 4Bayer Hispania, S.L., Sant Joan Despí, Barcelona, Spain

PCV110

MULTIVARIATE ANALYSIS OF CLINICAL AND PATIENT-LEVEL FACTORS ASSOCIATED WITH COLESEVELAM TREATMENT PERSISTENCE

 

Romanelli R1, Leahy A1, Jukes T1, Ye X2, Luan A2, Ishisaka D1
1Sutter Health, San Francisco, CA, USA, 2Daiichi Sankyo, Parsippany, NJ, USA

PCV111

UNMET THERAPEUTIC NEEDS FOR PATIENTS WITH DYSLIPIDEMIA ACCORDING TO ATP III GUIDELINES

 

Amand-Bourdon C1, Hopkins B2, Chou E2, Yang T3, Wang H2
1Sanofi, Chilly-Mazarin, France, 2Sanofi, Bridgewater, NJ, USA, 3Poplar Palace, Inc., Marlboro, NJ, USA

PCV112

DOSAGE ANALYSIS OF CHF THERAPIES ON THE BASIS OF HUNGARIAN CLAIM DATABASE

 

Tóth E1, Kovacs E1, Nagy B2
1Healthware Consulting Ltd., Budapest, Hungary, 2Healthware Ltd, Budapest, Hungary

PCV113

THE UTILISATION OF STATINS IN SLOVAK REPUBLIC

 

Gatialova K1, Bellova K2, Foltan V3, Majtás J2
1Pharmaceutical Faculty at Comenius University, Bratislava, Slovak Republic, 2Comenius University, Bratislava, Slovak Republic, 3Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic

PCV114

GENERIC SUBSTITUTION AND PRESCRIPTION IN SLOVAK HEALTH CONDITIONS

 

Snopkova M, Lagin A, Foltan V
Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic

PCV115

BURDEN OF HYPERTENSION IN SELECTED EU COUNTRIES: 2010 - 2025

 

Eichmann F, Potthoff P, Schmidt M
Kantar Health GmbH, München, Germany

PCV116

IMPACT OF THE TYPE OF DRUG INSURANCE ON COST OF STATINS AND ANTI-DEPRESSANTS

 

Blais L1, Kettani FZ2, Forget A1
1Université de Montréal, Montreal, QC, Canada, 2Université de Montréal, Montréal, QC, Canada

PCV117

A TEN YEARS LONGER LIFE: A THERAPEUTIC EDUCATION PROGRAM FOR HYPERTENSIVE PATIENTS

 

Menditto E1, D'Avino M2, Cammarota S1, Citarella A1, De Luca L1, Pistacchio L3, Riegler S1, Scala D2, Caruso D2
1CIRFF, Federico II University, Naples, Italy, 2Cardarelli Hospital, naples, Italy, 3University Federico II, Naples, Italy

PCV118

FIXED-DOSE COMBINATIONS AND THEIR VALUE TO PAYERS

 

Prüfert A, Andreykiv M, Nijhuis T
Quintiles, Hoofddorp, The Netherlands

PCV119

RETROSPECTIVE ANALYSIS OF PHARMACEUTICAL EXPENDITURES IN 2011 IN THE REPUBLIC OF SRPSKA

 

Guzvic V1, Zah V2
1National Insurance Fund, Banja Luka, Bosnia, 2Health Economics Consultant, Belgrade, Serbia and Montenegro

PCV120

THE FACTORS WHICH AFFECT THE PRICE OF ANTIHYPERTENSIVE COMBINATIONS INCLUDING ANGIOTENSIN RECEPTOR BLOCKERS

 

Berktas M, Guclu H, Ozbay L, Sencan N
Yeditepe University, Istanbul, Turkey

PCV121

RELATIONSHIP BETWEEN PRIMARY CARE PHYSICIANS PROFILE, SELF-PERCEIVED HEALTH AND RECOMMENDATIONS TO THEIR PATIENTS

 

Font B1, Lahoz R1, Roldan C1, Banegas JR2, Llisterri JL3, Lobos JM4, Gamarra J5, del Campo A6, Ruilope LM7
1Novartis Farmaceutica, Barcelona, Spain, 2Universidad Autónoma de Madrid/CIBERESP/IdiPaz, Madrid, Spain, 3C.S. Ingeniero Joaquín Benlloch, Valencia, Spain, 4C.S. Villablanca, Madrid, Spain, 5C.S. Medina del Campo Rural, Medina del Campo, Spain, 6Sociología y Comunicación, Madrid, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain

PCV122

HYPERTENSION AND DISABILITY-FREE LIFE EXPECTANCY FROM A COHORT STUDY IN JAPAN –RESULTS FROM A NATIONWIDE COHORT STUDY (NIPPON DATA80/90)–

 

Murakami Y1, Hayakawa T2, Miura K1, Ohkubo T1, Kita Y1, Takashima N1, Fujiyoshi A1, Okamura T3, Okayama A4, Ueshima H5, behave of NIPPON DATA80/90 Research Group .6
1Shiga University of Medical Science, Otsu, Shiga, Japan, 2Fukushima Medical University, Fukushima, Fukushima, Japan, 3Keio University, Shinjuku-ku, Tokyo, Japan, 4Japan Anti-Tuberculosis Association, Chiyoda-ku, Tokyo, Japan, 5Lifestyle-related Disease Prevention Centre, Otsu, Shiga, Japan, 6., ., ., Japan

PCV123

VIP STUDY: VENOUS THROMBOEMBOLISM PROPHYLAXIS PATTERNS AND DRUG USE IN PATIENTS UNDERGOING TOTAL KNEE AND HIP ARTHROPLASTY IN BRAZIL

 

Mainine S1, Nita ME2, Scheinberg M3, Vasconcelos P4, Guerra R5, Takemoto M6, Fujii RK7, Mould JF8, loures-Vale A9, Presa J10, Rached R2, Donato BMK11
1Hospital Estadual Mario Covas, Santo Andre, Sao Paulo, Brazil, 2Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 3Hospital AACD, Sao Paulo, Brazil, 4Hospital Santa Cruz, Sao Paulo, Brazil, 5ANOVA, Rio Janeiro, Brazil, 6ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 7Pfizer, Inc., São Paulo, São Paulo, Brazil, 8Pfizer, New York, NY, USA, 9Pfizer, sao paulo, Brazil, 10Pfizer Parmaceutics Inc., São Paulo, São Paulo, Brazil, 11Bristol-Myers Squibb Company, Wallingford, CT, USA

SESSION II – MONDAY, 5 NOVEMBER
SET-UP: Monday, 5 November 2012, 15:15 – 15:30
POSTER DISPLAY HOURS: Monday, 5 November 2012, 15:30 - 19:30
POSTER AUTHOR DISCUSSION HOUR: Monday, 5 November 2012, 18:30 – 19:30
DISMANTLE: Monday, 5 November 2012, 19:30

INFECTION – Clinical Outcomes Studies

PIN1

EFFECT OF ANTITUBERCOLOSIS TREATMENT ON LEVER ENZYMES

 

Hadida E
NCDC, Tripoli Libya, Tripoli, Libya

PIN2

ESTIMATING THE ADDITIVE EFFECTS OF LENGTH OF STAY ON CONTRACTING CLOSTRIDIUM DIFFICILE INFECTION

 

Wasserman M1, Roberts G2, Cylus J3, Latif F1
1Double Helix Consulting, London, UK, 2Double Helix Consulting Group, London, UK, 3European Observatory on Health Systems and Policies & London School of Economics and Political Science, London , UK

PIN3

BURDEN OF CYTOMEGALOVIRUS DISEASE IN IMMUNOSUPPRESSED PERSONS FOLLOWING TRANSPLANTATION IN FRANCE

 

Goryakin Y1, Ferchichi S2, Skanji D2, Odeyemi II3, Hakimi Z4, Aballea S5
1Creativ Ceutical, London, London, UK, 2Creativ Ceutical, Tunis, Tunisia, 3Astellas Pharma Europe Ltd., Middlesex , UK, 4Astellas Pharma Global Development, Leiderdorp, UK, 5Creativ-Ceutical, Paris, France

PIN4

MIXED-TREATMENT COMPARISON OF THE EFFICACY AND SAFETY OF ANTIRETROVIRAL DRUGS INDICATED FOR TREATMENT-EXPERIENCED HIV PATIENTS

 

Cure S1, Bianic F2, Shelbaya A3, Portsmouth S4, Jones EC5, Martin M1, Despiégel N2
1OptumInsight, Uxbridge, Middlesex, UK, 2OptumInsight, Nanterre, France, 3Pfizer, New York, NY, USA, 4Pfizer Inc., New York, NY, USA, 5OptumInsight, Uxbridge, UK

PIN5

EFFICACY OF CEFTAROLINE FOSAMIL AND OTHER INTRAVENOUS ANTIBIOTICS IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP): A NETWORK META-ANALYSIS (NMA)

 

Medic G1, Karabis A1, Borrill J2, Worrall J3, Bergman G1
1MAPI Consultancy, Houten, The Netherlands, 2AstraZeneca, Macclesfield, UK, 3AstraZeneca UK Ltd., Luton, UK

PIN6

SYSTEMATIC REVIEW OF NON-INTERFERON BASED REGIMENS FOR CHRONIC HEPATITIS C TREATMENT

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

PIN7

EFFICACY OF CEFTAROLINE FOSAMIL AND OTHER INTRAVENOUS ANTIBIOTICS IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): A NETWORK META-ANALYSIS (NMA)

 

Medic G1, Karabis A1, Borrill J2, Worrall J3, Bergman G1
1MAPI Consultancy, Houten, The Netherlands, 2AstraZeneca, Macclesfield, UK, 3AstraZeneca UK Ltd., Luton, UK

PIN8

A PRELIMINARY ECONOMICAL ANALYSIS BASED ON THE EARLY IMPACT OBSERVED ON GENITAL WARTS BURDEN REDUCTION FOLLOWING QUADRIVALENT HPV VACCINATION IN BELGIUM

 

Gobbo C1, Van Tielen R2, Bresse X3
1Spmsd, Brussels, Belgium, 2MLOZ, Brussels, Belgium, 3Sanofi Pasteur MSD, Lyon, France

PIN9

CONTRAINDICATIONS TO HEPATITIS C TREATMENT: WHICH ONES MODIFY THE LIKELIHOOD OF VETERANS RECEIVING TREATMENT?

 

Lafleur J, Lin J, Xie Y, Hayden C, DuVall S, Nelson RE
University of Utah, Salt Lake City, UT, USA

PIN10

FOURTH YEAR POST-ROTAVIRUS VACCINATION IN BELGIUM: DECREASE OF ROTAVIRUS-POSITIVE STOOL SAMPLES IN HOSPITALISED CHILDREN

 

Strens D1, Raes M2, Standaert B3
1Realidad, GRIMBERGEN, Vlaams Brabant, Belgium, 2Jessa Hospital, Hasselt, Belgium, 3GlaxoSmithKline Vaccines, Wavre, -, Belgium

PIN11

PHARMACOTHERAPY OF ACUTE BRONCHITIS IN CLINICS: RESULTS OF PHARMACOEPIDEMICAL RESEARCH

 

Zaytsev A, Kulagina I
The Main Military Clinical Burdenko Hospital, Moscow, Russia

PIN12

BURDEN OF DISEASE AND SEROTYPE DISTRIBUTION ASSOCIATED WITH REPORTABLE INVASIVE STREPTOCOCCUS PNEUMONIAE PNEUMONIA IN NORWAY, 2007–2009

 

Raluy M1, Gray S2, Lambrelli D1, Eriksson D1, Samantha M2, Wasiak R1, Myrvang B3
1United BioSource Corporation, London, UK, 2Pfizer, Collegeville, PA, USA, 3Norwegian Centre for Imported and Tropical Diseases, Oslo, Norway

PIN13

THE CLINICAL BURDEN OF HOSPITALIZED ALL-CAUSE PNEUMONIA IN THE LOMBARDIA AND PUGLIA REGIONS OF ITALY, 2007–2009

 

Lambrelli D1, Gray S2, Wasiak R1, Veronesi C3, Raluy M1, Munson S2, Buda S4, Icardi G5
1United BioSource Corporation, London, UK, 2Pfizer, Collegeville, PA, USA, 3CliCon S.r.l. Health, Economics & Outcomes Research, Ravenna, Italy, 4CliCon Srl, Ravenna, Italy, 5University of Genova, Genova, Genova, Italy

PIN14

PROJECTING THE CLINICAL IMPACT OF TREATING HEPATITIS C GENOTYPE 1 INFECTION WITH BOCEPREVIR IN GERMANY

 

Becker B1, Chhatwal J2, Ferrante S3, Elbasha EH3, Krobot KJ1
1MSD Sharp Dohme GmbH, Haar, Germany, 2University of Pittsburgh, Pittsburgh, PA, USA, 3Merck & Co. Inc., North Wales, PA, USA

PIN15

PREVALENCE OF HOSPITAL-ACQUIRED INFECTIONS IN INTENSIVE CARE UNITS AND ATTRIBUTABLE MORTALITY: DIFFERENT SOURCES OF DATA IN UNITED-STATES

 

Dubroca I1, Stemart A2, Amand-Bourdon C1, Joly F1
1Sanofi, Chilly-Mazarin, France, 2Aixial Pharma, Levallois-Perret, France

PIN16

TUBERCULOSIS TREATMENT OUTCOMES IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS

 

Khan AH1, Sulaiman SAS2, Abdul Muttalif AR3, Hassali MA4, Ahmad N5
1Universiti Sains Malaysia, Penang, Pulau Pinang, Malaysia, 2University Sains Malaysia, Penang, P.Pinang, Malaysia, 3Respiratory Institute of Malaysia,, Kula lumpur, Malaysia, Malaysia, 4Universiti Sains Malaysia, Minden, Penang, Malaysia, 5Universiti Sains Malaysia, Pinang, Penang, Malaysia

PIN17

TUBERCULOSIS TREATMENT OUTCOMES IN FOUR STATES OF MALAYSIA

 

Khan AH1, Syed Sulaiman SA2, Abdul Muttalif AR3, Hassali MA2, Ahmad N4
1Universiti Sains Malaysia, Penang, Pulau Pinang, Malaysia, 2Universiti Sains Malaysia, Minden, Penang, Malaysia, 3Institute of Respiratory Medicine, Kuala Lumpur, Kuala Lumpur, Malaysia, 4Universiti Sains Malaysia, Pinang, Penang, Malaysia

PIN18

RATES OF INFLUENZA COMPLICATIONS BY HIGH RISK GROUP

 

Mauskopf J1, Lee S2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Johnson & Johnson Pharmaceutical Services, LLC, Horsham, PA, USA

INFECTION – Cost Studies

PIN19

A BUDGET IMPACT (BI) ANALYSIS OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION (NOVAC) OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN THE UNITED KINGDOM

 

Jiang Y1, Gauthier A1, Keeping ST2, Carroll SM3
1Amaris, London, UK, 2Sanofi Pasteur MSD, Maidenhead, Berkshire, UK, 3Sanofi Pasteur MSD, Maidenhead, UK

PIN20

BUDGET IMPACT OF BACKBONE CHOICE IN ITALIAN TREATMENT- NAÏVE, HIV- INFECTED PATIENTS

 

Zaniolo O, Povero M, Pradelli L
AdRes HE&OR, Turin, Italy

PIN21

ECONOMIC IMPACT OF HOSPITAL-ACQUIRED INFECTIONS IN MECHANICALLY VENTILATED PATIENTS IN INTENSIVE CARE UNITS: RETROSPECTIVE ANALYSIS FROM A U.S. HOSPITAL DATABASE

 

Amand-Bourdon C1, Joly F1, Stemart A2
1Sanofi, Chilly-Mazarin, France, 2Aixial Pharma, Levallois-Perret, France

PIN22

ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN PERSONS OVER 50 YEARS OF AGE WITH UNDERLYING CHRONIC MEDICAL CONDITIONS IN FINLAND

 

Martikainen JA1, Soini EJ1, Laine J2, Åhman H2, Postila V2, Klemets P3
1ESiOR Oy, Kuopio, Finland, 2Pfizer Oy, Helsinki, Finland, 3Porvoo Hospital, Porvoo, Finland

PIN23

WITHDRAWN

 

 

PIN24

CLINICAL AND ECONOMIC EVALUATION OF AN ADULT PNEUMOCOCCAL VACCINATION PROGRAMME AIMED AT THE SPANISH HIV POPULATION

 

Guijarro P, Echave M
Pfizer Spain, Alcobendas, Madrid, Spain

PIN25

HEALTH AND ECONOMIC BENEFITS OF AVOIDING HOSPITAL PEN MOVES FOR DAIRY CATTLE IN THE UNITED STATES

 

Van Vlaenderen I1, Poulsen Nautrup B2, Postorino-Reeves N3, Cleale R3, Holland R3, Gasper S3
1CHESS, Ternat, Belgium, 2EAH Consulting, Juelich, Germany, 3Pfizer Animal Health Inc., Madison, NJ, USA

PIN26

REAL LIFE EFFECTIVENESS OF ANTIBIOTICS

 

Erdesz D1, Kis Z2
1MSD Pharma Hungary Ltd., Budapest, Hungary, 2Balassa János Hospital, Szekszard, Hungary

PIN27

COST ANALYSIS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN B FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HEMATOLOGIC PATIENTS IN GERMANY

 

Ostermann H1, Stephens J2, Gao X2, Weber B3, Charbonneau C4
1University Hospital Munich, Grosshadern, Munich, Germany, 2Pharmerit International, Bethesda, MD, USA, 3Pfizer, Berlin, Germany, 4Pfizer, Paris, France

PIN28

COST-OF-ILLNESS ANALYSIS OF CANDIDEMIA IN PATIENTS ON THE INTENSIVE CARE UNIT

 

Heimann S, Cornely OA, Wisplinghoff H, Vehreschild MJ, Franke B, Glossmann J, Vehreschild J
University Hospital of Cologne, Köln, Germany

PIN29

LENGTH OF STAY AND COST DUE TO RECURRENT CLOSTRIDIUM DIFFICILE INFECTIONS (CDI) AT A UNIVERSITY HOSPITAL IN FINLAND

 

Agthe N1, Mattila E2, Purmonen T1, Kanerva M2
1Oy Medfiles Ltd, Kuopio, Finland, 2Helsinki University Hospital, Helsinki, Finland

PIN30

VARICELLA, A COST OF ILLNESS HUNGARIAN STUDY

 

Tóth E1, Érsek K2
1Healthware Consulting Ltd., Budapest, Hungary, 2Corvinus University of Budapest, Budapest, Hungary

PIN31

BURDEN OF DISEASE AND ECONOMIC IMPACT OF DENGUE AND SEVERE DENGUE IN COLOMBIA: 2011

 

Castañeda-Orjuela CA1, Diaz H2, Camargo G2, Olarte F2, De la Hoz-Restrepo F1
1Universidad Nacional de Colombia, Bogota, NA, Colombia, 2Universidad Nacional de Colombia, Bogota, Bogota, Colombia

PIN32

ECONOMIC EVALUATION OF BOCEPREVIR FOR THE TREATMENT OF PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS INFECTION IN HUNGARY

 

Odhiambo R1, Chhatwal J2, Ferrante SA3, El Khoury A4, Elbasha E5
1MSD Pharma Hungary Kft., Budapest, Hungary, 2University of Pittsburgh, Pittsburgh, PA, USA, 3Merck Sharp and Dohme Corp., Whitehouse Station, NJ, USA, 4Merck Sharp and Dohme, Whitehouse Station, NJ, USA, 5Merck Sharp & Dohme Corp., Upper Gwynedd, PA, USA

PIN33

CORSAR-STUDY (COST AND RESOURCE UTILISATION STUDY IN ANTIRETROVIRAL TREATED PATIENTS):

 

Stoll M1, Kuhlmann A2, Hower M3, Heiken H4, Gerschmann S1, Klauke S5, Lutz T5, Bogner J6, Degen O7, van Lunzen J7, Bachmann C3, Stellbrink H8, Schmidt W9, Leistner I9, Mahlich JC10, Ranneberg B11
1Medizinische Hochschule Hannover, Hannover, Germany, 2Leibniz Universität Hannover, Hannover, Germany, 3Klinikum Dortmund, Dortmund, Germany, 4Private Practice, Hannover, Germany, 5Infektiologikum, Frankfurt, Germany, 6Universität München, Munich, Germany, 7Universität Hamburg, Hamburg, Germany, 8ICH Study Center, Hamburg, Germany, 9Ärzteforum Seestrasse, Berlin, Germany, 10Janssen-Cilag GmbH, Neuss, Nordrhein-Westfa, Germany, 11Janssen Cilag, Neuss, Germany

PIN34

DEVELOPMENT OF TREATMENT COSTS OF PATIENTS UNDERGOING REMISSION INDUCTION CHEMOTHERAPY: A HISTORICAL COMPARISON BEFORE AND AFTER INTRODUCTION OF POSACONAZOLE PROPHYLAXIS

 

Heimann S, Cornely OA, Wisplinghoff H, Vehreschild MJ, Franke B, Glossmann J, Vehreschild J
University Hospital of Cologne, Köln, Germany

PIN35

COST OF ANTIMICROBIAL PRESCRIBING USING A LARGE PHARMACY DATABASE IN SOUTH AFRICA

 

Truter I
Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa

PIN36

SIX YEARS OBSERVATIONAL STUDY OF THE COST OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND HIV/AIDS CONTROL

 

Dimitrova M1, Savova A1, Manova M1, Mitov K2, Stefanova M1, Petrova G3
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University Sofia, Faculty of Pharmacy, Sofia, Sofia, Bulgaria, 3Medical University, Faculty of Pharmacy, Sofia, Bulgaria

PIN37

THE ECONOMIC BURDEN OF INITIAL EMPIRIC ANTIBIOTIC FAILURE ON HEALTH CARE RESOURCE UTILIZATION FOR HOSPITALIZED PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAIS) IN GREECE

 

Athanasakis K1, Petrakis I2, Tsoulas C2, Vatopoulos A1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece

PIN38

REAL LIFE STUDY OF ANTIFUNGAL TREATMENT IN GREEK ICUS: THERAPEUTIC STRATEGY AND HOSPITAL RESOURCE UTILIZATION – ESTIMATOR STUDY

 

Armaganidis A1, Nanas S2, Antoniadou E3, Mandragos K4, Liakou K5, Kostagiolas L6, Koutsoukou A7, Baltopoulos G8, Nakos G9, Magkina A10, Katsaris G11, Prekates A12, Kompoti M13, Georgopoulos D14, Pneumatikos I15, Zakynthinos E16
1Second Critical Care Department, Attiko University Hospital, University of Athens Medical School, Athens, Greece, 21st Critical Care Department, Evangelismos Hospital, University of Athens, Athens, Greece, 3Intensive Care Unit, G. Gennimatas General Hospital, Thessaloniki, Greece, 4Intensive Care Unit, “Korgialenio Benakio” Red Cross Hospital of Athens, Athens, Greece, 5Medical Department, Astellas, Athens, Greece, 6Health Data Specialists Ltd, Athens, Greece, 7Intensive Care Unit, 1st Department of Respiratory Diseases, Sotiria Chest Hospital, University of Athens Medical School, Athens, Greece, 8Athens University School of Nursing, ICU at Ag. Anargyroi Hospital, Athens, Greece, 9Intensive Care Unit, University Hospital of Ioannina, Ioannina, Greece, 10Intensive Care Unit, Ag. Olga General Hospital, Athens, Greece, 11Intensive Care Unit, Piraeus General Hospital, Piraeus, Greece, 12General Intensive Care Unit, Tzaneio General Hospital, Piraeus, Greece, 13Intensive Care Unit, General Hospital of Eleusis “Thriassion”, Athens, Greece, 14Intensive Care Unit, University Hospital of Heraklion, Crete, Greece, 15Department of Intensive Care Medicine, University Hospital of Alexandroupolis, Alexandroupolis, Greece, 16Department of Critical Care, University Hospital of Larissa, Larissa, Greece

PIN39

A COST CONSEQUENCE ANALYSIS OF A QUADRIVALENT MENINGOCOCCAL VACCINE (MENACWY-TT) IN CANADA

 

Cognet M1, Jiang Y1, Parker M2, Demarteau N3, Bauch CT4
1Amaris, London, UK, 2University of Liverpool Management School, Liverpool, UK, 3GlaxoSmithKline Vaccines, Wavre, Belgium, 4University of Guelph, Guelph, ON, Canada

PIN40

COST-EFFECTIVENESS OF BOCEPREVIR-BASED TREATMENT OF CHRONIC GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

 

Becker B1, Chhatwal J2, Ferrante S3, Elbasha EH3, Krobot KJ1
1MSD Sharp Dohme GmbH, Haar, Germany, 2University of Pittsburgh, Pittsburgh, PA, USA, 3Merck & Co. Inc., North Wales, PA, USA

PIN41

COST-EFFECTIVENESS OF PERTUSSIS ADOLESCENT BOOSTER IN ENGLAND AND WALES: A DYNAMIC MODEL BASED ANALYSIS

 

Terlinden A1, Hardwick T2, Sauboin C1, Poirrier JE1
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2GlaxoSmithKline, London, UK

PIN42

COST-EFFECTIVENESS-ANALYSIS OF THE COMBINATION- THERAPY TELAPREVIR, PEG-IFNα2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS-C IN AUSTRIA

 

Said M, Dragosits A, Walter E
Institute for Pharmaeconomic Research, Vienna, Austria

PIN43

THE USE OF FUTILITY RULES IN ECONOMIC EVALUATIONS WITH DIRECT ACTING AGENTS (DAA) IN THE TREATMENT OF GENOTYPE 1 HEPATITIS C VIRUS (HCV) FROM A SPANISH HEALTH CARE PERSPECTIVE

 

D'Angelo ER1, Garcia Gonzalez I1, Simon MA2
1Janssen-Cilag SA, MADRID, MADRID, Spain, 2Hospital Clínico Universitario, ZARAGOZA, ARAGON, Spain

PIN44

COST-EFFECTIVENESS OF POSACONAZOLE COMPARED TO FLUCONAZOLE/ITRACONAZOLE FOR THE PREVENTION OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS

 

Athanasakis K, Petrakis I, Kyriopoulos J
National School of Public Health, Athens, Greece

PIN45

HEALTH ECONOMIC IMPACT OF INFANT VACCINATION PROGRAM WITH PHID-CV AND PCV13 USING NEW EFFICACY/EFFECTIVENESS DATA. EXAMPLE OF FINLAND

 

Delgleize E1, Torvinen S2
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2GlaxoSmithKline, Espoo, Finland

PIN46

PHARMACOECONOMIC EVALUATION OF THE INTRODUCTION OF UNIVERSAL VARICELLA VACCINATION IN ITALY

 

Sauboin C1, Bonanni P2, Ouwens MJ3, Era S4, Gabutti G5, Resti M6, Azzari C6, Vitale F7
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2University of florence, Florence, Italy, 3MAPI Consultancy, Houten, The Netherlands 4GlaxoSmithKline SpA Pharmaceuticals, Verona , Italy, 5Hygiene and Public Health, Chiavari (Genova), Italy, 6Meyer Paediatric University Hospital, Florence, Italy, 7University of Palermo, Palermo, Italy

PIN47

COST-EFFECTIVENESS ANALYSIS OF THE PRIMOVACCINATION OF NEWBORNS AGAINST TUBERCULOSIS IN SLOVAKIA

 

Marusakova E1, Bielik J2, Frecerova K3, Nevicka E3, Sedlakova D4
1GlaxoSmithKline Slovakia, Bratislava, Slovak Republic, 2Trencin University, Trencin, Slovak Republic, 3Healthcare Consultations, Bratislava, Slovak Republic, 4World Health Organization, Bratislava, Slovak Republic

PIN48

COST-EFECTIVENESS ANALYSIS OF DARUNAVIR VERSUS ATAZANAVIR, EACH IN COMBINATION WITH EMTRICITABINE AND TENOFOVIR, FOR THE MANAGEMENT OF NAIVE ANTI-RETROVIRAL HIV INFECTED PATIENTS, UNDER THE BELGIAN SOCIAL SECURITY PERSPECTIVE

 

Santos M1, Stenut S2, Ferraq W3, Legrand JC4, Tilleul P5, Borget I6
1Institut Gustave Roussy, Paris, Paris, France, 2Hopital Civil Charleroi, Charleroi, Belgium, 3Hôpital Mohamed VI, Marrakech, Morroco, Marrakech, Morocco, 4Hopital Civil Charleroi, Charleroi, Charleroi, Belgium, 5Groupe hospitalier Pitié-Salpêtrière, paris, France, 6Institut Gustave Roussy, Paris, France

PIN49

ECONOMIC EVALUATION OF 13-VALENT PNEUMOCOCCAL VACCINE IN HIGH RISK ELDERLY POPULATION, FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

 

Cruz RB1, Fernandes RA1, Takemoto M1, Cukier FN1, Fujii RK2, Roberts CS3, Presa J4, Jardim E4, Mould J3
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., São Paulo, São Paulo, Brazil, 3Pfizer, New York, NY, USA, 4Pfizer Parmaceutics Inc., São Paulo, São Paulo, Brazil

PIN50

A COST-EFFECTIVENESS ANALYSIS OF TELAPREVIR VERSUS BOCEPREVIR IN THE TREATMENT OF HEPATITIS C: A GREEK NATIONAL HEALTH SYSTEM PERSPECTIVE

 

Yfantopoulos J1, Paparouni K2, D'Angelo ER3
1National and Kapodistrian University of Athens, Athens, Greece, 2Janssen Cilag Pharmaceutical SACI, Athens, Greece, 3Janssen-Cilag SA, MADRID, MADRID, Spain

PIN51

HEALTH ECONOMIC EVALUATION OF THE VACCINATION AGAINST HERPES ZOSTER AND POSTHERPETIC NEURALGIA IN GERMANY

 

Ultsch B1, Reinhold T2, Siedler A3, Krause G3, Wichmann O3
1Robert Koch Institute / Charité Berlin, Berlin, Germany, 2Charite University Medical Center Berlin, Germany, Berlin, Germany, 3Robert Koch Institute, Berlin, Germany

PIN52

PHARMACOECONOMICAL ASPECTS OF TREATING ACUTE BRONCHITIS AMONG ADULTS

 

Kulagina I, Zaytsev A
The Main Military Clinical Burdenko Hospital, Moscow, Russia

PIN53

THE COST EFFECTIVENESS OF MATERNAL AND INFANT ANTIRETROVIRAL REGIMENS TO PREVENT VERTICAL TRANSMISSION IN A RESOURCE POOR COUNTRY

 

Revill P1, Walker S1, Sculpher MJ2, Merry C3, Barry M4, Ryan M3
1University of York, York, UK, 2University of York, Heslington, UK, 3Trinity College Dublin, Dublin, Ireland, 4St. James's Hospital, Dublin, Ireland, Ireland

PIN54

EVALUATION OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION

 

Yagudina R1, Kulikov A2, Zinchuk I2
1First Moscow State Medical University named after I. M. Sechenov, Moscow, Moscow, Russia, 2First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia

PIN55

HOW SHOULD WE TARGET COST-EFFICACY IN THE TREATMENT OF HIV-1 NAÏVE PATIENTS WITH RECOMMENDED THERAPIES BASED ON NNRTIS IN SPAIN?

 

Gostkorzewicz J, Ledesma F
Janssen, Madrid, Madrid, Spain

PIN56

ECONOMIC VALUE OF TELAPREVIR FOR THE TREATMENT OF PREVIOUSLY UNTREATED F2 FIBROSIS CHRONIC HEPATITIS C PATIENTS

 

Gavart S1, Lee S2, D'Angelo ER3, DeMasi R4, Cure S5, Bianic F6
1Janssen Pharmaceutica, Beerse, Belgium, 2Janssen Global Services, Companies of Johnson & Johnson, Horsham, PA, USA, 3Janssen-Cilag SA, MADRID, MADRID, Spain, 4Janssen Research & Development, LLC, Titusville , NJ, USA, 5OptumInsight, Uxbridge, Middlesex, UK, 6OptumInsight, Nanterre, France

PIN57

ECONOMIC EVALUATION OF 13-VALENT PNEUMOCOCCAL VACCINE IN HIGH RISK PEDIATRIC POPULATION, FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

 

Cruz RB1, Fernandes RA1, Takemoto M1, Cukier FN1, Fujii RK2, Roberts CS3, Presa J4, Jardim E4, Mould J3
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., São Paulo, São Paulo, Brazil, 3Pfizer, New York, NY, USA, 4Pfizer Parmaceutics Inc., São Paulo, São Paulo, Brazil

PIN58

COST PER SUSTAINED VIROLOGICAL RESPONSE OF TELAPREVIR AND BOCEPREVIR IN THE TREATMENT OF GENOTYPE 1 HEPATITIS C PATIENTS ACCORDING TO THE PREVIOUS TREATMENT RESPONSE AND THE METAVIR GROUPS IN BRAZIL

 

Morais AD, Pereira ML
Janssen Cilag Farmaceutica, São Paulo, Brazil

PIN59

COST-EFFECTIVENESS OF AMOXICILLIN CLAVULANATE DIRECTED TOWARDS THE APPLICATION OF INDICATED AT PRIMARY CARE IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE RHINOSINUSITIS, TONSILLOPHARYNGITIS, AND ACUTE OTITIS MEDIA

 

Malhan S1, Oksuz E2, Eray O3, Koc E4
1Baskent University, Anakara, Turkey, 2Baskent University, Ankara, Turkey, 3GlaxoSmithKline, Istanbul , Turkey, 4GlaxoSmithKline, Istanbul, Turkey

PIN60

CRITICAL REVIEW OF COST-EFFECTIVENESS ANALYSES OF HUMAN PAPILLOMAVIRUS VACCINE IN BOYS

 

Jiang Y1, Gauthier A1, Préaud E2, Largeron N2
1Amaris, London, UK, 2Sanofi Pasteur MSD, Lyon, France

PIN61

THE COST-UTILITY OF TELAPREVIR IN COMBINATION WITH PEGINTERFEON ALPHA AND RIBAVIRIN (PR) AS COMPARED TO THE COMBINATION BOCEPREVIR WITH PR AND TO PR ALONE IN THE MANAGEMENT OF CHRONIC HEPATITIS C IN THE NETHERLANDS

 

Vellopoulou K1, Van Agthoven M2, Van Der Kolk A2, Lamotte M1, Cure S3, Bianic F4
1IMS Health, Vilvoorde, Belgium, 2Janssen-Cilag BV, Tilburg, The Netherlands, 3OptumInsight, Uxbridge, Middlesex, UK, 4OptumInsight, Nanterre, France

PIN62

COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR FOR THE TREATMENT OF TREATMENT-NAïVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS IN GERMANY

 

Stahmeyer JT1, Schauer S1, Wirth D2, Fleischmann J3, Lee S4, Gavart S5, Bianic F6, Cure S7, Krauth C1
1Hannover Medical School, Hannover, Germany, 2Janssen-Cilag GmbH, Neuss, Germany, 3Janssen-Cilag Germany, Neuss, Germany, 4Janssen Global Services, Companies of Johnson & Johnson, Horsham, PA, USA, 5Janssen Pharmaceutica, Beerse, Belgium, 6OptumInsight, Nanterre, France, 7OptumInsight, Uxbridge, UK

PIN63

VACCINATION AGAINST HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE: A COST-EFFECTIVENESS ANALYSIS

 

Bresse X1, Annemans L2, Bloch K1, Duru G3, Gauthier A4
1Sanofi Pasteur MSD, Lyon, France, 2Ghent University & Brussels University, Ghent, Belgium, 3Cyklad Group, Rillieux la Pape, France, 4Amaris, London, UK

PIN64

ASSESSING THE COST-EFFECTIVENESS (CE) OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC) IN THE UNITED KINGDOM

 

Jiang Y1, Gauthier A1, Keeping ST2, Carroll SM3
1Amaris, London, UK, 2Sanofi Pasteur MSD, Maidenhead, Berkshire, UK, 3Sanofi Pasteur MSD, Maidenhead, UK

PIN65

COST-EFFECTIVENESS OF FIRST-LINE ANTIRETROVIRAL REGIMENS FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN COLOMBIA: AN ANALYSIS OF LOPINAVIR/RITONAVIR (LPV/R) AND DARUNAVIR PLUS RITONAVIR (DRV+RTV) IN TREATMENT-NAÏVE PATIENTS

 

Moller J1, Desai K2, Simpson KN3, Baran R4, Dietz B5, Van de Steen O6
1United BioSource Corporation, Eslov, Sweden, 2United BioSource Corporation, London, UK, 3Medical University of South Carolina, Charleston, SC, USA, 4Abbott Laboratories, Abbott Park, IL, USA, 5Abbott GmbH & Co. KG, Ludwigshafen, Germany, 6Abbott Laboratories, Wavre, IL, Belgium

PIN66

COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN SÃO PAULO STATE, BRAZIL – PUBLIC PERSPECTIVE

 

Fujii RK1, Roberts CS2, Mould J2, Presa J3, Jardim E3, Manfrin DF4
1Pfizer, Inc., São Paulo, São Paulo, Brazil, 2Pfizer, New York, NY, USA, 3Pfizer Parmaceutics Inc., São Paulo, São Paulo, Brazil, 4Pfizer, Inc., São Paulo, SP, Brazil

PIN67

COST MINIMIZATION COMPARISON OF A VACCINATION WITH CAMPAIGN PROGRAM FOR CORPORATIONS USING PCV13 VESUS FREE PCV10 WITH PAID CAMPAIGN

 

Fujii RK1, Mould J2, Roberts CS2, Presa J3, Jardim E3
1Pfizer, Inc., São Paulo, São Paulo, Brazil, 2Pfizer, New York, NY, USA, 3Pfizer Parmaceutics Inc., São Paulo, São Paulo, Brazil

PIN68

COST-MINIMIZATION ANALYSIS OF CASPOFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF FEBRILE, NEUTROPENIC PATIENTS WITH A PRESUMED FUNGAL INFECTION IN THE NETHERLANDS

 

Charokopou M1, Majer IM1, Van der Waal JM2, Verheggen BG3
1Pharmerit International, Rotterdam, Zuid-Holland, The Netherlands, 2Merck Sharp & Dohme BV, Haarlem, Noord-Holland, The Netherlands, 3Pharmerit International, Rotterdam, The Netherlands

PIN69

COST UTILITY ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN MALAYSIA

 

Wu DBC1, Lee KK2, Lee VW3, Hong LW4, Roberts CS5
1Monash University Sunway Campus, Kuala Lumpur, Malaysia, 2Monash University Sunway Campus, Selangor, Malaysia, 3The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, 4Pfizer (Malaysia) Sdn Bhd, Shah Alam, Selangor, Malaysia, 5Pfizer, New York, NY, USA

PIN70

COST-EFFECTIVENESS OF AN INDIVIDUALIZED APPROACH IN THE TREATMENT OF HBEAG-NEGATIVE CHB PATIENTS WITH PEGINTERFERON ALFA-2A IN ITALY

 

Iannazzo S1, Espinós B2, Coco B3, Brunetto M3, Rossetti F4, Caputo A4, Bonino F3
1IMS HEOR, Milan, Italy, 2IMS HEOR, Barcelona, Spain, 3University Hospital (AOUP), Pisa, Italy, 4Roche Spa, Monza, Italy

PIN71

THE POTENTIAL PUBLIC HEALTH BENEFIT OF PNEUMOCOCCAL CONJUGATE VACCINES IN KAZAKHSTAN

 

Nurgozhin T1, Yermekbaeva B1, Topachevskyi O2
1Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan, 2GlaxoSmithKline Vaccines, Wavre, Belgium

PIN72

COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB WITH RISK FACTORS FOR RESPIRATORY SYNCYTIAL VIRUS PREVENTION

 

Lee MY, Lee EK
Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea

PIN73

DIRECT MEDICAL COSTS AND HEALTH CARE RESOURCE USE ASSOCIATED WITH HEPATIS C INFECTION IN PORTUGAL

 

Laires P1, Pereira R2, Calinas F3, Marinho RT4, Martins AP1
1Merck, Sharp & Dohme, Oeiras, Portugal, 2Merck Sharp & Dohme, Lda., LISBON, Portugal, 3Hospital de Santo António dos Capuchos, Lisbon, Portugal, 4Hospital Santa Maria, Lisbon, Portugal

PIN74

COST SAVINGS DUE TO ANTIBIOTIC PRESCRIPTION RELATED TO QUICK C-REACTIVE PROTEIN TESTING

 

Tesar T1, Babela R2
1Union Health Insurance Fund, Bratislava, Slovak Republic, 2St. Elizabeth University of Heath and Social Sciences, Bratislava, Slovak Republic

INFECTION – Patient-Reported Outcomes & Patient Preference Studies

PIN75

HEALTH-RELATED QUALITY OF LIFE OF CLOSTRIDIUM DIFFICILE INFECTION: A METHODOLOGICAL CONTRIBUTION TO DIRECT UTILITY ELICITATION BY TTO

 

Shupo F1, Dorey J2, Aballea S3, McGarry T4, Odeyemi II5, Toumi M6
1Creativ-Ceutical, London, UK, 2Creativ Ceutical, Paris, France, 3Creativ-Ceutical, Paris, France, 4Accent, London, UK, 5Astellas Pharma Europe Ltd., Middlesex , UK, 6University Claude Bernard Lyon 1, Lyon, France

PIN76

HEALTH RELATED QUALITY OF LIFE OF HIV INFECTED INTRAVENOUS DRUG USERS

 

Surah S1, Adams R2, Townsend L3, Reynolds I3, Delamere S3, Kinahan J4, Mulcahy F1, Keenan E4, Lyons F1, Barry M5
1GUIDE Clinic, St. James Hospital, Dublin, Ireland, 2NCPE, St James's Hospital, Dublin, Ireland, 3GUIDE Clinic, St. James Hospital, Dublin, dublin, Ireland, 4DTCB, Dublin, Ireland, 5St. James's Hospital, Dublin, Ireland, Ireland

PIN77

ELICITATION OF HEALTH-RELATED QUALITY OF LIFE CONCEPTS ASSOCIATED WITH CYTOMEGALOVIRUS IN TRANSPLANT RECIPIENTS

 

Hakimi N1, Dorey J2, Hakimi Z3, Aballea S1, Odeyemi II4, Toumi M5
1Creativ-Ceutical, Paris, France, 2Creativ Ceutical, Paris, France, 3Astellas Pharma Global Development, Leiderdorp, UK, 4Astellas Pharma Europe Ltd., Middlesex , UK, 5University Claude Bernard Lyon 1, Lyon, France

PIN78

TREATMENT PREFERENCE ATTRIBUTES AMONG PRIMARY IMMUNODEFICIENCY PATIENTS AND CAREGIVERS RECEIVING IMMUNOGLOBULIN THERAPY

 

Iyer R1, Luo M2, Olding L3, Sondhi S4
1Baxter Healthcare Corporation, Deerfield, IL, USA, 2Baxter BioScience, Deerfield, IL, USA, 3Bryter, London, UK, 4Baxter Healthcare Corporation, Compton, UK

INFECTION – Health Care Use & Policy Studies

PIN79

HEPATITIS C VIRUS INFECTION INCREASES THE RISK OF ALZHEIMER'S DISEASES

 

Chiu WC1, Chen PC2
1Cathay General Hospital, Taipei, Taiwan, 2College of Public Health, National Taiwan University, Taipei, Taiwan

PIN80

MULTIVARIATE COX ANALYSIS REGARDING TREATMENT SWITCH ON CHRONIC HEPATITIS B (CHB) DISEASE MANAGEMENT BASED ON A 2-YEAR PROSPECTIVE STUDY IN 5 EUROPEAN (EU) COUNTRIES

 

Arama V1, Zeuzem S2, Leblebicioglu H3, Simon K4, Klauck I5, Morais E5, Lescrauwaet B6, Kamar D7, Zarski J8
1Carol Davila University of Medicine and Pharmacy, Prof. Dr. M. Bals National Institute of Infection Diseases, Bucharest, Romania, 2J.W. Goethe University Hospital, Medicine Departements, Frankfurt, Germany, 3Medical School Samsun, Ondokuz Mayis University, Samsun, Turkey, 4Wroclaw University of Medicine, Wrocalw, Poland, 5Bristol-Myers Squibb, Rueil Malmaison, France, 6Xintera Consulting, Leuven, Belgium, 7DOCS, Sèvres, France, 8Clinique Universitaire d'Hépato-Gastroentérologie, CHU de Grenoble, Grenoble, France

PIN81

PERCEPTIONS OF HOSPITAL PHARMACISTS REGARDING EFFECTIVE ANTI-MALARIAL DRUG MANAGEMENT IN PAKISTAN. A QUALITATIVE INSIGHT

 

Malik M1, Hassali MA2, Shaffie A3
1University Sains Malaysia, penang, Malaysia, 2Universiti Sains Malaysia, Penang, Palau Pinang, Malaysia, 3USM, penang, Malaysia

PIN82

THE MACRO-ECONOMIC IMPACT OF REDUCING MALARIA: AN APPLICATION OF A DYNAMIC GENERAL EQUILIBRIUM MODELLING TO GHANA

 

Yerushalmi E1, Hunt PE2, Hoorens S3, Sauboin C4, Smith RD5
1The University of Warwick, Coventry, UK, 2RAND Corporation, Santa Monica, CA, USA, 3RAND Corporation, Brussels, Belgium, 4GlaxoSmithKline Vaccines, Wavre, Belgium, 5London School of Hygiene & Tropical Medicine, London, Holborn, UK

PIN83

NATIONAL IMMUNIZATION TECHNICAL ADVISORY GROUP (NITAG) DECISION-MAKING PROCESS FOR VACCINE RECOMMENDATION: OVERVIEW AND ANALYSIS

 

Ricciardi WG1, Duvillard R2, Dankó D3, Duru G4, Picazo J5, Poland G6, Weil-Olivier C7, Toumi M8
1Catholic University of Sacred Heart, Rome, Italy, 2Creativ-Ceutical, Paris, France, 3Corvinus University of Budapest, Budapest, Hungary, 4Cyklad Group, rilleux la Pape, France, 5University Complutense of Madrid, Madrid, Spain, 6Mayo Clinic, Rochester, MN, USA, 7University Paris VII Diderot, Paris, France, 8University Claude Bernard Lyon 1, Lyon, France

PIN84

TRENDS IN PREVALENCE OF ANTIBACTERIAL DRUG USE AMONG DUTCH CHILDREN FROM 2005 UNTIL 2010

 

Joosten SGL1, Houweling LMA2, Penning FJA2
1Utrecht University, Utrecht, The Netherlands, 2PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PIN85

BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS BACTEREMIA ON HOSPITALS IN THE UNITED STATES: RESULTS FROM A NATIONAL DATABASE

 

Kamble S, Shah AJ, Gemmen E
Quintiles Outcome, Rockville, MD, USA

PIN86

CLINICAL AND ECONOMIC BURDEN OF COMMUNITY ACQUIRED PNEUMONIA IN 7 COUNTRIES. A COMPARISON WITH INVASIVE PNEUMOCOCCAL DISEASE

 

Delgleize E, Topachevskyi O
GlaxoSmithKline Vaccines, Wavre, Belgium

PIN87

LENGT OF STAY AND COSTS FOR PATIENTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTIONS IN SWEDEN

 

Norén T1, Bruce S2, Fagerlund K3, Nordling S3
1Department of Infectious Diseases, Örebro, Sweden, 2IMS Health, Stockholm, Sweden, 3Astellas Pharma Nordic, Kastrup, Denmark

PIN88

COST IMPLICATIONS OF DIFFERENT PRACTICES IN VACCINE PROVISION

 

Maervoet J, Pasmans R, Saka Ö
Deloitte, Diegem, Belgium

PIN89

EUROPEAN REFERENCE PRICING FOR VACCINES IN GERMANY: MECHANICS AND EFFECTS

 

Hammerschmidt T1, Barth J2
1GlaxoSmithKline, Munich, Germany, 2-, Feucht, Germany

PIN90

TOWARDS BEST PRACTICES FOR HANDLING UNCERTAINTIES IN HEALTH TECHNOLOGY ASSESSMENTS FOR HPV VACCINATION TO BETTER INFORM DECISION MAKING

 

Siebert U1, Castellsague X2, Lee Mortensen G3, La Torre G4
1UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria, 2Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat (Barcelona), Spain, 3AnthroConsult, Aarhus C, Denmark, 4Sapienza University of Roma, Roma, Italy

SESSION II – MONDAY, 5 NOVEMBER
SET-UP: Monday, 5 November 2012, 15:15 – 15:30
POSTER DISPLAY HOURS: Monday, 5 November 2012, 15:30 - 19:30
POSTER AUTHOR DISCUSSION HOUR: Monday, 5 November 2012, 18:30 – 19:30
DISMANTLE: Monday, 5 November 2012, 19:30

MEDICAL DEVICE/DIAGNOSTICS – Clinical Outcomes Studies

PMD1

ECONOMIC VALUE OF SCREENING FOR EARLY PARKINSON'S DISEASE IN A EUROPEAN SETTING

 

Johnson S1, Birnbaum HG1, Kaltenboeck A2, Diener M2, Siderowf A3
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3University of Pennsylvania, Philadelphia, PA, USA

PMD2

HEMATOLOGIC CANCERS: DIAGNOSTIC TESTING PATTERNS AND THE ROLE OF SPECIALTY LABORATORIES IN THE AGE OF PERSONALIZED MEDICINE

 

Engel-Nitz NM1, Eckert B2, Song R1, Koka P1, Hulbert E1, McPheeters J1, Teitelbaum A3
1OptumInsight, Eden Prairie, MN, USA, 2Novartis Molecular Diagnostics, Cambridge, MA, USA, 3OptumInsight, San Diego, CA, USA

PMD3

PRE-SCREENING TOOLS: A NEGLECTED APPROACH TO DIAGNOSE AND CUT COST ASSOCIATED WITH OSTEOPOROSIS

 

Khan Y, Sarriff A, Hayat Khan A, Hassali, A
University Sains Malaysia, penang, penang, Malaysia

PMD4

WITHDRAWN

 

 

PMD5

CLINICAL AND COST-EFFECTIVENESS OF THIRD-GENERATION, IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICES FOR PEOPLE WITH END-STAGE HEART FAILURE: A SYSTEMATIC REVIEW

 

Jaworska E, Wlodarczyk A, Budasz-Swiderska M
Agency for Health Technology Assessment In Poland (AHTAPol), Warsaw, Poland

PMD6

EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATMENT OF PATIENTS WITH ACUTE OR CHRONIC GRAFT VERSUS HOST DISEASE (GVHD), REFRACTORY TO CORTICOSTEROIDS – A SYTEMATIC REVIEW

 

Walczak J1, Miernik K1, Kuter I1, Ussowicz M2
1Arcana Institute, Cracow, Poland, 2Wroclaw Medical University, Wroclaw, Poland

PMD7

WITHDRAWN

 

 

PMD8

ONE YEAR EVALUATION OF EFFECTIVENESS AND DEVICE COMPLICATION OUTCOMES IN THE HELPING EVALUATE REDUCTION IN OBESITY (HERO) STUDY

 

Cobourn C1, Torre MO2, Degboe AN3, Burk CT4, Robinson JM2, Diegidio RF5
1Surgical Weight Loss Centre, Mississauga, Ontario, Canada, 2Allergan Medical, Goleta, CA, USA, 3Allergan, Inc., Irvine, CA, USA, 4Allergan, Inc., Laguna Beach, CA, USA, 5Allergan, Inc., Bedminster, NJ, USA

MEDICAL DEVICE/DIAGNOSTICS – Cost Studies

PMD9

A COMPARATIVE ASSESSMENT OF COST IMPLICATIONS OF NOVEL DRUG VERSUS NOVEL DEVICE-BASED TREATMENTS FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

 

Armstrong S1, Amorosi S2, Peppa R3, Da Deppo L4, Garfield S1
1GfK Bridgehead, Wayland, MA, USA, 2Boston Scientific, Natick, MA, USA, 3Boston Scientific, Genova, Italy, 4Boston Scientific, Milan, Italy

PMD10

ANALYSIS OF COSTS OF COMPLICATIONS FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS, COMPARING DOSE-ADJUSTED WARFARIN TO LEFT ATRIAL APPENDAGE CLOSURE

 

Armstrong S1, Amorosi S2, Peppa R3, Da Deppo L4, Garfield S1
1GfK Bridgehead, Wayland, MA, USA, 2Boston Scientific, Natick, MA, USA, 3Boston Scientific, Genova, Italy, 4Boston Scientific, Milan, Italy

PMD11

THE COST OF POOR SAMPLE QUALITY: ASSESSING THE FINANCIAL IMPACT OF SAMPLE REJECTION AND RECOLLECTION IN HEALTH CARE INSITUTIONS

 

Chait G1, Schleuter K2, Scraba K3, Baginska E4, Flynn L5, Church S6
1Whythawk Ltd, Oxford, Oxfordshire, UK, 2BD Diagnostics Preanalytical Systems, Heidelberg, Germany, 3BD Diagnostics Preanalytical Systems, Mississauga, Ontario , Canada, 4BD, Mississauga, Ontario, Cambodia, 5BD Diagnostics Preanalytical Systems, Franklin Lakes, NJ, USA, 6BD Diagnostics Preanalytical Systems, Oxford, Oxfordshire, UK

PMD12

A BUDGET IMPACT MODEL TO INVESTIGATE POTENTIAL COST SAVINGS ASSOCIATED WITH THE USE OF SAFETY-ENGINEERED SHARP DEVICES IN BELGIUM

 

Hanmore E1, Ruff L1, Maclaine GDH2, Garin F3, Alonso A4, Leroy N5
1Medaxial Group, London, London, UK, 2Becton, Dickinson UK Ltd, Oxford, Oxfordshire, UK, 3Becton, Dickinson SA, Madrid, Madrid, Spain, 4BD Medical - Medical Surgical Systems, Erembodegem-Aalst, Belgium, 5Becton, Dickinson Benelux NV, Erembodegem, Aalst, Belgium

PMD13

PROJECTED ECONOMIC IMPACT OF UTILIZING FRACTIONAL FLOW RESERVE (FFR)-GUIDED VERSUS CORONARY ANGIOGRAPHY-GUIDED PERCUTANEOUS CORONARY INTERVENTIONS (PCI) IN PATIENTS WITH MULTIVESSEL CORONARY DISEASE: A BUDGET IMPACT MODEL

 

Soliman AM1, Domyahn M2
1College of Pharmacy, University of Minnesota, Minneapolis, MN, USA, 2St. Jude Medical, Minneapolis, MN, USA

PMD14

POTENTIAL IMPACT OF REGIONAL CEREBRAL OXYGEN SATURATION MONITORING DURING CORONARY ARTERY BYPASS SURGERY ON THE PATIENT REIMBURSEMENT BUDGET IN TURKEY

 

Kockaya G1, Akin O2, Ott M3, Erslon MG4, Kelley SD5
1Covidien, Ankara, Turkey, 2Covidien, Istanbul, Turkey, 3Covidien, Zurich, Switzerland, 4Covidien, Boulder, CO, USA, 5Covidien, Mansfield, MA, USA

PMD15

BUDGET IMPACT ANALYSIS OF VASCULAR CLOSURE DEVICES (VCDS) IN ITALY AND SPAIN

 

Nazareth T1, Busutil R2, Perrone F3, Espallardo O2, Mauro E3, Saadi R1
1Cordis Corporation, a Johnson & Johnson Company, Bridgewater Township, NJ, USA, 2Johnson & Johnson Medical, Madrid, Madrid, Spain, 3Johnson & Johnson Medical, Pratica di Mare - Pomezia, Roma, Italy

PMD16

THE BUDGETARY IMPACT OF USING THE SIMTOMAX® TESTING KIT FOR THE DIAGNOSIS OF COELIAC DISEASE IN THE UNITED KINGDOM

 

Shields GE1, Brereton NJ1, Little K2
1BresMed, Sheffield, UK, 2Tillotts Pharma AG, Rheinfelden, Switzerland

PMD17

USE OF STERRAD® STERILIZERS RESULTS IN COST-SAVINGS COMPARED TO STEAM STERILIZATION IN AN ITALIAN HOSPITAL SETTING

 

Perrone F1, Zenna G1, Mauro E1, Hamerslag L2, Emmermann A3
1Johnson & Johnson Medical Italy, Pomezia (RM), Italy, 2Costello Medical Consulting Ltd., Cambridge, UK, 3Advanced Sterilization Products, Norderstedt, Germany

PMD18

INTRODUCTION OF NOVEL BIOMARKER TESTING FOR OVARIAN CANCER: BUDGET IMPACT ANALYSIS FOR AN ITALIAN REGIONAL HEALTH CARE SERVICE

 

Romagnolo C1, Maggino T2, Gion M3, Berto P4
1Obstet. Gynecol. Dept., G. Fracastoro Hospital, San Bonifacio (Verona),, Verona, Veneto, Italy, 2Obstet. Gynecol. Dept, Mestre, Venezia, Veneto, Italy, 3Regional Center Biological Markers, Mestre, Venezia, Veneto, Italy, 4University of Padova and Analytica Laser, Verona, Italy

PMD19

BUDGET IMPACT ANALYSIS OF BALLOON SINUPLASTY VERSUS CLASSIC FUNCTIONAL ENDOSCOPIC SINUS SURGERY. USING A BUDGET IMPACT MODEL TO IDENTIFY COUNTRY SPECIFIC MARKET ACCESS STRATEGY

 

Sorgeloose T1, Demaire C2, Stueve M3
1Johnson & Johnson Medical, Acclarent, Diegem, Belgium, 2Johnson & Johnson Medical, Acclarent, Issy Les Moulineaux , France, 3Johnson & Johnson Medical, Norderstedt, Germany

PMD20

BUDGET IMPACT OF DRUG ELUTING BALLOONS FOR INTERMITTENT CLAUDICATION FROM SUPERFICIAL FEMORAL ARTERY DISEASE IN THE U.S. HEALTH CARE SYSTEM

 

Pietzsch JB1, Geisler BP1, Jaff MR2
1Wing Tech Inc., Menlo Park, CA, USA, 2Mass General Hospital, Boston, MA, USA

PMD21

COST COMPARISON OF SPINAL FUSION PROCEDURES WITH GRAFTON MIXED WITH LOCAL BONE COMPARED TO ILIAC CREST BONE

 

Borgman B
Medtronic Trading Sàrl., Tolochenaz, Switzerland

PMD22

FINANCIAL IMPACT OF ADOPTING IMPLANTABLE LOOP RECORDER (ILR) DIAGNOSTICS (REVEAL®) FOR UNEXPLAINED SYNCOPE IN PORTUGAL: COMPARISON WITH CONVENTIONAL DIAGNOSTIC PATHWAYS

 

Providencia R1, Morais C2, Reis H3, Elvas L1, Candeias R4, Sanfins V5, Farinha S6, Tsintzos S7
1Centro Hospitalar e Universitário de Coimbra, S.Martinho do Bispo, Coimbra, Portugal, 2Hospital Prof. Dr. Fernando da Fonseca, Amadora, Amadora, Portugal, 3Hospital de Santo Antonio, Oporto, Porto, Portugal, 4Hospital Distrital de Faro, Faro, Faro, Portugal, 5Centro Hospitalar do Alto Ave, Fafe, Fafe, Portugal, 6Medtronic Portugal, Lisbon, Portugal, 7Medtronic, Mounds View, MN, USA

PMD23

LONG-TERM CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF CATHETER-BASED RENAL DENERVATION IN THE UNITED KINGDOM. A MODEL-BASED PROJECTION BASED ON THE SYMPLICITY HTN-2 TRIAL

 

Pietzsch JB1, Geisler BP1, Akehurst RL2
1Wing Tech Inc., Menlo Park, CA, USA, 2University of Sheffield, Sheffield, UK

PMD24

ECONOMICAL ASPECTS OF THE REIMBURSEMENT OF EXTRACORPOREAL PHOTOPHERESIS (ECP) IN TREATMENT OF PATIENTS WITH GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) WHO ARE REFRACTORY TO STEROID TREATMENT

 

Walczak J1, Wepsiec K1, Lemanski T1, Zawieja J1, Ussowicz M2
1Arcana Institute, Cracow, Poland, 2Wroclaw Medical University, Wroclaw, Poland

PMD25

FINANCIAL IMPACT OF ADAPTIVE CARDIAC RESYNCHRONIZATION THERAPY (ACRT) DEVICE ALGORITHMS IN THE UNITED KIGDOM, GERMANY, AUSTRALIA AND CANADA: ARE THERE SAVINGS ASSOCIATED WITH DEVICE SELECTION?

 

Tarab AD1, Dougher CE1, Rogers TB2, Bril SL3, Tsintzos S3, Brown B4, Chapman M5, Klesius A6, Eggleston A7, Sadri H8, Goss T1, Veath BK9
1Boston Healthcare Associates, Inc., Boston, MA, USA, 2Medtronic, Inc., Mounds View, MN, USA, 3Medtronic, Mounds View, MN, USA, 4Medtronic International Trading Sarl, Tolochenaz, Switzerland, 5Medtronic Limited, Watford, Hertfordshire, UK, 6Medtronic GmbH, Meerbusch, Nordrhein-Westfa, Germany, 7Medtronic International Ltd., North Ryde, NSW, Australia, 8Medtronic of Canada, Brampton, ON, Canada, 9Medtronic International Ltd., Mounds View, MN, USA

PMD26

COST EFFECTIVENESS OF HIV TESTING IN NON-TRADITIONAL SETTINGS – THE HINTS STUDY

 

Pizzo E1, Rayment M2, Thornton A3, Sullivan A2
1Imperial College London, CLAHRC, London, UK, 2Directorate of HIV/GU Medicine, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, 3UCL, London, UK

PMD27

BUDGET IMPACT OF SELECTING CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES WITH ADAPTIVE (“ACRT”) PROGRAMMING ALGORITHMS UNDER THE UNITED STATES MEDICARE PAYMENT SETTING

 

Tarab AD1, Dougher CE1, Rogers TB2, Bril SL2, Tsintzos S3, Goss T1, Veath BK2
1Boston Healthcare Associates, Inc., Boston, MA, USA, 2Medtronic, Inc., Mounds View, MN, USA, 3Medtronic, Mounds View, MN, USA

PMD28

COMPARING THE COST AND DIAGNOSTIC EFFICIENCY OF GADOXETIC ACID-ENHANCED MRI VERSUS EXTRACELLULAR CONTRAST MEDIA-ENHANCED MRI AND MULTIDETECTOR COMPUTED TOMOGRAPHY IN PATIENTS WITH SUSPECTED HEPATOCELLULAR CARCINOMA IN THAILAND AND KOREA

 

Holtorf AP1, Bergmann K2, Kim MJ3, Phongkitkarun S4, Sobhonslidsuk A5, Rinde H6, Lee JM7
1Health Outcomes Strategies, GmbH, Basel, Switzerland, 2Bayer HealthCare, Berlin, Germany, 3Severance Hospital, Seoul, South Korea, 4Ramathibodi Hospital Mahidol University, Bangkok, Thailand, 5Ramathibodi Hospital, Bangkok, Thailand, 6BioBridge Strategies, Binningen, BL, Switzerland, 7Seoul National University Hospital, Seoul, South Korea

PMD29

COMPARING THE ECONOMIC IMPACT OF PROSTHESIS CHOICE IN UNICOMPARTMENTAL KNEE ARTHROPLASTY PROCEDURES: DEVELOPMENT OF AN ECONOMIC MODEL

 

Mattli R1, Balliere A1, Menzie AM2
1Zimmer GmbH, Winterthur, Zurich, Switzerland, 2Zimmer, Minneapolis, MN, USA

PMD30

SHORT TERM HEALTH-ECONOMIC OUTCOMES OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) IN TYPE 1 DIABETES: A COST COMPARISON ANALYSIS

 

Fortwaengler K1, Rautenberg T2, Caruso A1
1Roche Diagnostics GmbH, Mannheim, Germany, 2Assessment In Medicine AiM GmbH, Lörrach, Germany, Germany

PMD31

IMPACT OF USING A VESSEL SEALER SYSTEM AND THE HARMONIC SCALPEL IN HOSPITAL OUTCOMES AND COST OF THYROIDECTOMY PROCEDURES

 

Silva FB1, Limoeiro ACO1, Del Bianco J1, Sardenberg C1, Teich V2, Teich N2
1Albert Einstein Hospital, SÃO PAULO, Brazil, 2Medinsight – Decisions in Health Care, SÃO PAULO, Brazil

PMD32

OUTCOMES AND COSTS OF ISOLATED AORTIC VALVE REPLACEMENTS ASSOCIATED WITH THE MINI-INVASIVE IMPLANTATION OF A NEW SUTURELESS AND COLLAPSED VALVE IN ITALY, FRANCE, GERMANY, AND UNITED KINGDOM

 

Pradelli L1, Zaniolo O1, Giardina S2, Ranucci M3
1AdRes HE&OR, Turin, Italy, 2Sorin Group, Saluggia, Italy, 3IRCSS Policlinico San Donato, San Donato Milanese, Italy

PMD33

THE IMPACT OF THREE DIFFERENT IMAGING STRATEGIES ON SURGERY PLANNING FOR PATIENTS WITH COLORECTAL CANCER LIVER METASTASES

 

Rinde H1, Zech CJ2, Jonas E3, Bergmann K4, Holtorf AP5
1BioBridge Strategies, Binningen, BL, Switzerland, 2Klinikum der Universität München, Munich, Germany, 3University Hospital CLINTEC, Karolinska Institutet, Stockholm, Sweden, 4Bayer HealthCare Medical Care GMA, Berlin, Germany, 5Health Outcomes Strategies, GmbH, Basel, Switzerland

PMD34

ECONOMIC COMPARATIVE EVALUATION OF A SURGICAL FILM DRESSING IN THE MANAGEMENT OF POST-OPERATIVE SURGICAL WOUNDS. AN INEXEPENSIVE AND SIMPLE SOLUTION TO A COSTLY PROBLEM

 

Trueman P1, Torra i Bou JE2, Verdú Soriano J3, Lopez Casanova P4, Abejón Arroyo A5
1Smith&Nephew, Sant Joan Despí, Barcelona, Spain, 2Smith&Nephew, Sant Joan Despi, Barcelona, Spain, 3Universidad de Alicante, Sant Joan Despí, Barcelona, Sri Lanka, 4Hospital de Elche, Sant Joan Despí, Barcelona, Spain, 5Hospital Clínico Universitario de Valladolid, Sant Joan Despi, Barcelona, Spain

PMD35

COST ANALYSIS OF AN IMPLANTABLE LOOP RECORDER, REVEAL© XT, FOR THE DIAGNOSIS OF ATRIAL FIBRILLATION IN PATIENTS WHO UNDERWENT CRYPTOGENIC STROKE FROM THE PERSPECTIVE OF A TERTIARY SPANISH HOSPITAL

 

Bravo Y1, Martí B2, Grifols MA3
1Hospital General Yagüe, Burgos, Castilla León, Spain, 2Medtronic Iberia, Madrid, Spain, 3Medtronic Ibérica, Madrid, Madrid, Spain

PMD36

COST-ANALYSIS OF PCR GUIDED PRE-EMPTIVE ANTIBIOTIC TREATMENT OF S.AUREUS-INFECTIONS: AN ANALYTIC DECISION MODEL

 

Hübner C1, Hübner NO2, Kramer A2, Fleßa S1
1University of Greifswald, Greifswald, Germany, 2University Hospital of Greifswald, Greifswald, Germany

PMD37

FORECASTING THE PREVALENCE AND ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN SELECTED COUNTRIES, 2010 - 2025

 

Rizzo JA1, Mallow P2, Cirrincione A3
1Stony Brook University, Port Jeffeso, NY, USA, 2S2 Statistical Solutions, Cincinnati, OH, USA, 3Biosense Webster, Inc, Diamond Bar, CA, Belgium

PMD38

THE COST BURDEN OF UNEXPLAINED SYNCOPE IN FIVE EUROPEAN COUNTRIES: A DATABASE ANALYSIS

 

Eggington S1, Tsintzos S2, Collignon C3, Borghetti F4, Martí B5, Sicras-Mainar A6
1Medtronic International Trading Sarl, Tolochenaz, Switzerland, 2Medtronic, Mounds View, MN, USA, 3Medtronic France SAS, Boulogne, France, 4Medtronic Italia, Sesto San Giovanni, Italy, 5Medtronic Iberia, Madrid, Spain, 6Badalona Serveis Assistencials, Badalona, Barcelona, Spain

PMD39

THE ECONOMIC BURDEN OF ATRIAL FIBRILLATION AMONG ELDERLY POPULATIONS IN SELECTED DEVELOPED COUNTRIES

 

Rizzo JA1, Mallow P2, Cirrincione A3
1Stony Brook University, Port Jefferson, NY, USA, 2S2 Statistical Solutions, Cincinnati, OH, USA, 3Biosense Webster, Inc, Diamond Bar, CA, Belgium

PMD40

BURDEN OF SSI IN GASTROINTESTINAL, CARDIAC AND ORTHOPAEDIC SURGERIES IN KOREA

 

Kostrzewska K1, Tsao J2, Jung AR3, Plisko R1
1HTA Consulting, Krakow, Poland, 2Johnson & Johnson Medical Asia-Pacific, Singapore, Singapore, 3Johnson and Johnson Medical Asia-Pacific, Seoul, South Korea

PMD41

ECONOMIC EVALUATION OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION FOR CHILDREN WITH DIABETES – A PILOT STUDY

 

Petkova E, Petkova V, Petrova G
Medical University, Faculty of Pharmacy, Sofia, Bulgaria

PMD42

THE INCIDENCE OF THYROID CANCER AND MEDICAL COST AMONG PATIENTS WITH THYROID NODULES IN KOREA : USING HEALTH CLAIM DATABASE

 

Kim J1, Hyun MK1, Kwon JW1, Park YJ2
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Seoul National University College of Medicine, Seoul, South Korea

PMD43

COMPARISON OF ACTUAL COSTS VERSUS DRG REVENUE OF CERVICAL ARTHROPLASTY IN PATIENTS WITH DEGENERATIVE DISC DISEASE IN GERMANY

 

Banz K1, Welker C2, Finsterwald D3
1Outcomes International, Basel, Basel, Switzerland, 2Synthes GmbH, Umkirch , Germany, 3Synthes GmbH, Zuchwil, Switzerland

PMD44

EVALUATING STRATEGIES FOR USING DNA TESTING TO IDENTIFY MUCINOUS PANCREATIC CYSTS

 

Myers JA1, Klein RW1, Han X1, Al-Haddad MA2, Smolen HJ1
1Medical Decision Modeling Inc., Indianapolis, IN, USA, 2Indiana University School of Medicine, Indianapolis, IN, USA

PMD45

ESTIMATING ECONOMIC IMPACT OF ANGIOGENESIS-SPECIFIC IMAGING IN METASTATIC BREAST CANCER

 

Bodnar C1, Paramore LC2, Knopf KB3
1GE Healthcare, Bucks, UK, 2United BioSource Corporation, Lexington, MA, USA, 3Pacific Hematology Oncology Associates, San Francisco, CA, USA

PMD46

ECONOMIC ANALYSIS OF A PREDICTIVE TEST FOR TAXANE RESPONSE IN EARLY BREAST CANCER PATIENTS IN THE UK

 

Bodnar C1, Brown RE2, Knopf KB3
1GE Healthcare, Bucks, UK, 2United BioSource Corporation, Bethesda , MD, USA, 3Pacific Hematology Oncology Associates, San Francisco, CA, USA

PMD47

ECONOMIC EVALUATION OF REDUCED FUTILE 1ST LINE THERAPY IN METASTATIC RENAL CELL CARCINOMA PATIENTS USING EARLY ANGIOGENESIS-SPECIFIC IMAGING

 

Bodnar C1, Gruschkus SK2, Dhamane A3, Shah M2
1GE Healthcare, Bucks, UK, 2Xcenda, LLC, Palm Harbor, FL, USA, 3Xcenda, LLC, Suite 500, FL, USA

PMD48

STRUCTURED SMBG IN IRANIAN PEOPLE WITH TYPE 2 DIABETES: A COST CONSEQUENCE ANALYSIS

 

Aghili R1, Khamseh ME1, Malek M1, Yarahmadi S2, Farshchi A1
1Tehran University of Medical Sciences, Tehran, Iran, 2Ministry of Health and Medical Education, Tehran, Iran

PMD49

COST-EFFECTIVENESS OF THE TLC-NOSF DRESSING IN VENOUS LEG ULCERS

 

Maunoury F1, Motrunich A1, Fortin S2
1Statésia, Le Mans, France, 2Laboratoires URGO, Chenôve, France

PMD50

COST-EFFECTIVENESS ANALYSIS OF FOUR VALIDATED TECHNIQUES OF ACCELERATED PARTIAL BREAST IRRADIATION FOR THE TREATMENT OF EARLY-STAGE BREAST CANCER: SPANISH PUBLIC HEALTH SYSTEM STANDARD ESTIMATIONS

 

Santos M1, Guerra JLL2, Gordillo MJO3, Fondevilla A2, Calvo F2, Samblás J2, Marsiglia H2
1Institut Gustave Roussy, Paris, Paris, France, 2Instituto Madrileño de Oncologia, Madrid, Madrid, Spain, 3Hospital Universitario Virgem del Rocio, Seville, Andaluzia, Spain

PMD51

COST-EFFECTIVENESS OF A PREDICTIVE TEST OF THE BENEFIT OF CHEMOTHERAPY

 

Laas E1, Vataire AL2, Aballea S2, Gligorov J1, Rouzier R1, Chéreau E1
1Tenon Hospital, Paris, France, 2Creativ-Ceutical, Paris, France

PMD52

DIAGNOSTICS IN COST-EFFECTIVENESS ANALYSIS: THE EVALUATION OF THE EOS 2D/3D X-RAY IMAGING SYSTEM

 

Faria R1, McKenna C2, Sculpher MJ3
1University of York, York, North Yorkshire, UK, 2University of York, York, UK, 3University of York, Heslington, UK

PMD53

MODELING THE HEALTH AND ECONOMIC CONSEQENCES OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN NON-INSULIN TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN

 

Dirani R1, Diago-Cabezudo JI2, Willis W3
1LifeScan, Inc., West Chester, PA, USA, 2LifeScan EMEA, Madrid, Spain, 3LifeScan EMEA, Johnson & Johnson, Buckinghamshire, UK

PMD54

TRANS-CATHETER AORTIC VALVE IMPLANTATION FOR THE NON-OPERATIVE MANAGEMENT OF AORTIC STENOSIS: A COST-EFFECTIVENESS ANALYSIS

 

Racz J1, Ewara E2, Martin J3, Sarma S1, Chu MW4, Schlachta CM4, Zaric G5
1The University of Western Ontario Schulich School of Medicine and Dentistry, London, ON, Canada, 2University of Western Ontario, London, ON, Canada, 3London Health Sciences Center and The University of Western Ontario Schulich School of Medicine and Dentistry, London, ON, Canada, 4The University of Western Ontario Schulich School of Medicine and Dentistry and London Health Sciences Center, London, ON, Canada, 5Richard Ivey School of Business and The University of Western Ontario Schulich School of Medicine and Dentistry, London, ON, Canada

PMD55

SACRAL NERVE MODULATION (SNM) FOR THE TREATMENT OF IDIOPATHIC REFRACTORY OVERACTIVE BLADDER: COST-EFFECTIVE IN THE UK COMPARED TO OPTIMAL MEDICAL THERAPY, BOTULINUM TOXIN A (BONT-A) AND PERCUTANEOUS TIBIAL NERVE STIMULATION (PTNS)

 

Walleser S1, Betts C2, Hallas N3, Ockrim J4
1Medtronic International Trading Sarl, Tolochenaz, Switzerland, Switzerland, 2Salford Royal NHS Foundation Trust, Salford, UK, 3Medtronic Limited, Watford, Hertfordshire, UK, 4University College London Hospitals, London, London, UK

PMD56

COST-EFECTIVENESS ANALYSIS COMPARING THE APPLICATION OR NOT OF WHOLE BRAIN IRRADIATION BEFORE STEREOTECTIC RADIOSURGERY FOR THE TREATMENT OF ONE TO FOUR BRAIN METASTASES, ACCORDING TO BRAZILIANS THIRD-PARTY PRIVATE PAYER'S PERSPECTIVE

 

Santos M1, Stefani SD2, Dias R3, Palma A4, Neto JPR5, Campos ESD6
1Institut Gustave Roussy, Paris, France, 2Hospital Mãe de Deus, Porto Alegre, RS, Brazil, 3Saude Suplementar, Florianopolis, Santa Catarina, Brazil, 4Federação das Unimeds do Rio de Janeiro, Rio de Janeiro, RJ, Brazil, 5Capesesp, Rio de Janeiro, RJ, Brazil, 6Federação das Unimeds de Santa Catarina, Univille University, Joinville, SC, Brazil

PMD57

THE COSTS-EFFECTIVENESS OF COBAN 2 FOR THE TREATMENT OF VENOUS LEG ULCERS IN THE NETHERLANDS

 

Nuijten M1, Vos A2, Wigbers-van Wezel M3
1Ars Accessus Medica, Amsterdam (Jisp), The Netherlands, 23M Medical Markets, zoeterwoude, The Netherlands, 33M Healthcare Benelux, zoeterwoude, The Netherlands

PMD58

COST-EFFECTIVENESS ANALYSIS OF LEPROSY CASE DETECTION METHODS IN NORTHERN NIGERIA

 

Ezenduka CC1, Post E2, Namadi A3, John S4, Suraj A5, Onwujekwe O6
1Nnamdi Azikiwe University, Awka, Anambra state, Nigeria, 2Royal Tropical Institute (KIT), Amsterdam , The Netherlands, 3The Netherlands Leprosy Relief, Jos, Plataeu state, Nigeria, 4Adamawa State Ministry of Health, Yola, Adamawa state, Nigeria, 5Gombe State Ministry of Health, Gombe, Gombe sate, Nigeria, 6University of Nigeria, Enugu, Enugu sate, Nigeria

PMD59

WITHDRAWN

 

 

PMD60

THE COSTS-EFFECTIVENESS OF 3M™ COBANTM 2 LAYER COMPRESSION SYSTEM (COBAN 2) FOR THE TREATMENT OF LYMPHOEDEMA IN THE NETHERLANDS

 

Nuijten M1, Vos A2, Wigbers-van Wezel M3
1Ars Accessus Medica, Amsterdam (Jisp), The Netherlands, 23M Medical Markets, zoeterwoude, The Netherlands, 33M Healthcare Benelux, zoeterwoude, The Netherlands

PMD61

COST-EFFECTIVENESS OF POSITRON EMISSION TOMOGRAPHY IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW

 

Zaim R1, Redekop WK1, de Bree R2, van Dongen GAMS2, Hoekstra OS2, Uyl-de Groot CA1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Center, Amsterdam, The Netherlands

PMD62

COST-EFFECTIVENESS IN DIAGNOSTIC TESTS: COMPARISON OF THE IBD PRE-ENDOSCOPIC SCREENING F-CALPROTECTIN TEST VERSUS SEROLOGIC MARKERS IN SELECTED EUROPEAN MARKETS

 

Mascialino B1, Hermansson LL1, Larsson A2
1Thermo Fisher Scientific, Uppsala, Sweden, 2Uppsala University, Uppsala, Sweden

PMD63

A REVIEW OF ECONOMIC EVALUATION MODELS FOR CARDIAC RESYNCHRONIZATION THERAPY WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN PATIENTS WITH HEART FAILURE

 

Tomini F, van Asselt AD
Maastricht University Clinical Center, Maastricht, Limburg, The Netherlands

PMD64

CAN MOLECULAR ALLERGOLOGY IMPROVE ALLERGEN-SPECIFIC IMMUNOTHERAPY ADHERENCE AND PATIENT QUALITY OF LIFE IN A COMPLEX POLLEN AREA?

 

Hermansson LL1, Mascialino B1, Sastre J2
1Thermo Fisher Scientific, Uppsala, Sweden, 2Fundacion Jimenes Diaz, Madrid, Spain

PMD65

THE COST EFFECTIVENESS OF HAND HELD ULTRASOUND SCANNING FOR AAA IN ELDERLY SUBJECTS WITH A HISTORY OF SMOKING

 

Phiri D1, Mallow P2, Rizzo JA3
1General Electric Health Care, Bucks, London, UK, 2S2 Statistical Solutions, Cincinnati, OH, USA, 3Stony Brook University, Port Jeffeso, NY, USA

PMD66

HEALTH-ECONOMIC ANALYSIS OF THE SYSTEMATIC USE OF SINGLE-HAND SECURED HUBER NEEDLES (POSITIVE-PRESSURE) IN FRENCH HOSPITALS

 

Bénard S1, Tournier C1, Levert H2, Douard MC2, Villiers S2, Albert O2
1St[è]Ve Consultants, Oullins, France, 2Hôpital Saint-Louis, Paris, France

PMD67

THE COST EFFECTIVENESS OF PLATELET RICH PLASMA VERSUS CORTICOSTEROIDS IN THE TREATMENT OF LATERAL EPICONDYLITIS

 

Peerbooms JC1, Gosens T2, Poole C3, Jorgensen E4
1Albert Schweitzer hospital, Dordrecht, The Netherlands, 2St. Elisabeth Hospital, Tilburg, The Netherlands, 3Cardiff University, Cardiff, UK, 4Biomet Nordic, Oslo, Norway

PMD68

COST-EFFECTIVENESS OF SACRAL NEUROMODULATION IN THE TREATMENT OF IDIOPATHIC WET REFRACTORY OVERACTIVE BLADDER IN ITALY

 

D'Ausilio A1, Bertapelle P2, Vottero M2, Del Popolo G3, Giannantoni A4, Ostardo E5, Spinelli M6
1HEAD Consulting, Milan, Italy, Italy, 2Azienda Ospedaliera CTO/Maria Adelaide, Torino, Italy, Italy, 3Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy, Italy, 4Università di Perugia, Perugia, Italy, Italy, 5Azienda Ospedaliera Santa Maria degli Angeli, Pordenone, Italy, Italy, 6Ospedale Niguarda Ca' Granda, Milano, Italy, Italy

PMD69

COST-EFFECTIVENESS OF CATHETER ABLATION VERSUS ANTIARRHYTHMIC DRUG THERAPY FOR THE TREATMENT OF ATRIAL FIBRILLATION IN THE UNITED KINGDOM

 

Rizzo JA1, Mallow P2, Cirrincione A3
1Stony Brook University, Port Jeffeso, NY, USA, 2S2 Statistical Solutions, Cincinnati, OH, USA, 3Biosense Webster, Inc, Diamond Bar, CA, Belgium

PMD70

A FIVE-YEAR MARKOV MODEL EVALUATING THE COST-UTILITY OF NASHA/DX FOR THE TREATMENT OF FECAL INCONTINENCE: A UNITED STATES PERSPECTIVE

 

Wexner SD1, Bernstein M2, Purdy C3, Magar R4
1Cleveland Clinic Florida, Weston, FL, USA, 2NYU Langone Medical Center, New York, NY, USA, 3AHRM Inc., Buffalo, NY, USA, 4AHRM Inc., Raleigh, NC, USA

PMD71

THE SWITCH STUDY: THE IMPACT OF CONTINUOUS GLUCOSE MONITORING ON HEALTH CARE RESOURCE UTILIZATION

 

de Portu S1, Castaneda J2, Hommel E3, Olsen BS4, Battelino T5, Conget I6, Schutz-Fuhrmann I7, Hoogma R8, Schierloh U9, Sulli N10, Bolinder J11, Gough H12
1Medtronic International Sàrl, Tolochenaz, Switzerland, 2Medtronic Bakken Research Center, Maastricht, The Netherlands, 3Steno Diabetes Center, Gentofte, Denmark, 4Herlev Hospital, Herlev, Denmark, 5University Children's Hospital, Ljubljana, Slovenia, 6ICMDM Hospital Clínic i Universitari, Barcelona, Spain, 7Hospital Hietzing, Vienna, Austria, 8Groene Hart Ziekenhuis, Gouda , The Netherlands, 9Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg, 10Policlinico Umberto I, Rome, Italy, 11Karolinska University Hospital, Stockholm, Sweden, 12Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland

MEDICAL DEVICE/DIAGNOSTICS – Patient-Reported Outcomes & Patient Preference Studies

PMD72

THE USE OF MULTI-CRITERIA DECISION ANALYSIS TO ELICIT COLORECTAL CANCER SCREENING PREFERENCES

 

Hummel JM, Steuten L, Groothuis-Oudshoorn KGM, Mulder N, IJzerman MJ
University of Twente, Enschede, The Netherlands

PMD73

QUALITY OF LIFE AND RESOURCE USE AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION. PRELIMINARY RESULTS OF AN OBSERVATIONAL MULTICENTRE STUDY

 

Ribera A1, Ferreira-González I2, Slof J3, Cascant P1, Abdul-Jawad O1, Marsal JR1, Garcia del Blanco B1, Serra V1, Falces C4, Andrea R4, Gutiérrez E5, del Valle R6, Mota P7, López D8, Tornos P1, Garcia-Dorado D1
1Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain, 2Vall d'Hebron University Hospital, Barcelona , Barcelona , Spain, 3Universitat Autonoma de Barcelona, Bellaterra, Spain, 4Hospital Clínic i Provincial de Barcelona, Barcelona, Barcelona, Spain, 5Hospital Gregorio Marañón, Madrid, Madrid, Spain, 6Hospital Central de Asturias, Oviedo, Oviedo, Spain, 7Hospital Clínico de Valladolid, Valladolid, Valladolid, Spain, 8Hospital Clínico de Santiago, Santiago de Compostela, a Coruña, Spain

PMD74

THE RELATIONSHIP BETWEEN TREATMENT SATISFACTION AND HEALTH STATUS AMONG THOSE WITH TYPE 1 DIABETES

 

Pignot M1, Eichmann F2, DiBonaventura MD3
1Kantar Health, München, Bavaria, Germany, 2Kantar Health GmbH, München, Germany, 3Kantar Health, New York, NY, USA

PMD75

DOES PRESENTING FOLLOW-UP TEST INFORMATION AFFECT PEOPLE'S PREFERENCES FOR COLORECTAL CANCER SCREENING TESTS? A DISCRETE CHOICE EXPERIMENT

 

Benning T1, Dellaert B1, Severens J1, Dirksen C2
1EUR, Rotterdam, The Netherlands, 2Clinical and Medical Technology Assessment, AZ Maastricht, The Netherlands

PMD76

THE EFFECT OF INSULIN PUMP THERAPY ON HEALTH STATUS AMONG THOSE WITH TYPE 1 DIABETES

 

Pignot M1, Eichmann F2, DiBonaventura MD3
1Kantar Health, München, Bavaria, Germany, 2Kantar Health GmbH, München, Germany, 3Kantar Health, New York, NY, USA

PMD77

CONTRIBUTION OF INDIVIDUAL EQ-5D DIMENSIONS TO IMPROVED QUALITY OF LIFE AFTER BALLOON KYPHOPLASTY FOR VERTEBRAL COMPRESSION FRACTURES

 

Borgström F1, Aghayev E2, Olafsson G1, Miltenburger C3
1Quantify Research, Stockholm, Stockholm, Sweden, 2IEFO, University of Bern, Bern, Switzerland, 3Medtronic International, Tolochenaz, Switzerland

PMD78

THE SWITCH STUDY: THE IMPACT OF CONTINUOUS GLUCOSE MONITORING ON QUALITY OF LIFE AND TREATMENT SATISFACTION

 

Gough H1, Castaneda J2, Hommel E3, Olsen BS4, Battelino T5, Conget I6, Schutz-Fuhrmann I7, Hoogma R8, Schierloh U9, Sulli N10, Bolinder J11, de Portu S12
1Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland, 2Medtronic Bakken Research Center, Maastricht, The Netherlands, 3Steno Diabetes Center, Gentofte, Denmark, 4Herlev Hospital, Herlev, Denmark, 5University Children's Hospital, Ljubljana, Slovenia, 6ICMDM Hospital Clínic i Universitari, Barcelona, Spain, 7Hospital Hietzing, Vienna, Austria, 8Groene Hart Ziekenhuis, Gouda , The Netherlands, 9Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg, 10Policlinico Umberto I, Rome, Italy, 11Karolinska University Hospital, Stockholm, Sweden, 12Medtronic International Sàrl, Tolochenaz, Switzerland

MEDICAL DEVICE/DIAGNOSTICS – Health Care Use & Policy Studies

PMD79

A POPULATION-BASED STUDY ON THE USE OF BLOOD GLUCOSE MONITORING TEST STRIPS

 

Gregoire JP1, Breton MC2, Sauriol L3, Moisan J1
1Université Laval, Québec, QC, Canada, 2Chair on adherence to treatments - Université Laval, Québec, QC, Canada, 3Sanofi-Aventis, Laval, QC, Canada

PMD80

PREFERENCES FOR A NEW IMAGING TECHNIQUE TO DETECT BREAST CANCER

 

Roelvink J, Hummel JM, Tije EM, Til JAV, IJzerman MJ
University of Twente, Enschede, The Netherlands

PMD81

EVALUATION OF PRODUCT WASTAGE FROM MODERN HUMAN GROWTH HORMONE ADMINISTRATION DEVICES

 

Kappelgaard AM1, Wisniewski T2, Seitz L3, Pollock RF4, Qian Y5
1Novo Nordisk A/S, Søborg, Gladsaxe, Denmark, 2Novo Nordisk, Inc., Princeton, NJ, USA, 3Novo Nordisk Pharma GmbH, Mainz, Rhineland-Palati, Germany, 4Ossian Health Economics and Communications, Basel, Switzerland, 5Novo Nordisk A/S, Hillerød, Region Hovedstad, Denmark

PMD82

IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN ITALY FROM 2000 TO 2008: A POPULATION-BASED ANALYSIS USING HEALTH ADMINISTRATIVE DATABASES

 

Madotto F1, Fornari C1, Conti S2, Borghetti F3, Mantovani LG4, Cesana G1
1University of Milano - Bicocca, Monza, Italy, 2University of Milano - Bicocca, Monza (MB), Italy, 3Medtronic Italia, Sesto San Giovanni, Italy, 4Federico II University of Naples, Naples , Italy

PMD83

THE COST IMPACT OF MODIFYING PATTERNS OF SELF-MONITORING OF BLOOD GLUCOSE IN AN IRISH TYPE 2 DIABETES COHORT

 

Usher C1, O'Leary A2, Mulhall C2, Barry M3
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin 8, Ireland, 3St. James's Hospital, Dublin, Ireland, Ireland

PMD84

TELEMONITORING AFTER DISCHARGE WITH HEART FAILURE - COST-EFFECTIVENESS MODELLING OF ALTERNATIVE SERVICE DESIGNS

 

Brennan A1, Thokala P2, Baalbaki H1, Stevens JW1, Wang J1, Pandor A3
1University of Sheffield, Sheffield, UK, 2University of Sheffield, SHEFFIELD, UK, 3The University of Sheffield, Sheffield, South Yorkshire, UK

PMD85

AGENT-BASED CARDIOVASCULAR DISEASE MODEL FOR INDIA

 

Higashi M1, Horblyuk R2, North M3, Graziano D3, Macal C3, Sarawate C4, Kruzikas D2, Collier N3
1GE Healthcare, Palatine, IL, USA, 2GE Healthcare, Wauwatosa, WI, USA, 3Argonne National Laboratory, Argonne, IL, USA, 4GE Healthcare, Bangalore, Karnataka , India

PMD86

INAPPROPRIATE USE OF UPPER GASTROINTESTINAL ENDOSCOPY IN CLINICAL PRACTICES IN JAPAN

 

Hamashima C1, Goto R2, Sano H3
1National Cancer Center of Japan, Tokyo, Japan, 2Kyoto University, Kyoto, Kyoto, Japan, 3Shiga University, Hikone-city, Shiga, Japan

PMD87

STUDY OF FASTING PLASMA GLUCOSE WITH CENTRAL OBESITY IN MIDDLE AGED PERIMENOPAUSAL WOMEN

 

Ashok P1, Balsubramanian B2, Joshi AR3
1Bharati Vidyapeeth Medical College ,Pune, Pune, India, 2Bharati Medical College, Pune, India, 3Bharati Medical College, pune, India

PMD88

DISPARITIES IN ACCESS TO EGFR-MUTATION TESTING IN PATIENTS WITH ADVANCED NSCLC IN GERMANY 2011

 

Kellermann L1, Ukena D2
1OncologyInformationService, Freiburg, Germany, 2Klinikum Bremen-Ost GmbH, Bremen, Germany

PMD89

DIAGNOSTIC ACCURACY OF EARLY BIOMARKERS FOR ACUTE CORONARY SYNDROME (ACS)

 

Carroll C1, Goodacre S1, Stevens J1, Al Khalaf M1, Leaviss J1, Wang J1, Collinson P2
1University of Sheffield, Sheffield, UK, 2St George's Hospital, London, UK

PMD90

RENAL DENERVATION FOR RESISTANT HYPERTENSION: HTA REPORT OF THE VENETO REGION

 

Lopatriello S1, Filippi C2, Bassotto F3, Redomi A1, Scroccaro G4
1UVEF-CTRDM, Verona, Italy, 2Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy, 3UVEF -CTRDM, Verona, Italy, 4Regione del Veneto, Venezia, Italy

PMD91

SCENARIO ANALYSIS AND REAL OPTIONS MODELING OF HOME BRAIN MONITORING IN EPILEPSY PATIENTS

 

IJzerman MJ, Breteler M
University of Twente, Enschede, The Netherlands

PMD92

INHALER USE IN FIVE EUROPEAN COUNTRIES: ANALYSIS OF SALES DATA FROM Q4 2005 TO Q4 2011

 

Price D1, Marshall J2, Turner R2
1University of Aberdeen, Aberdeen, UK, 2Mundipharma International Ltd, Cambridge, UK

PMD93

PRACTICE VARIATION IN DIAGNOSTIC IMAGING WORKUP AND TREATMENT CRITERIA FOLLOWING A RECENT TIA OR MINOR ISCHEMIC STROKE: CONSEQUENCES FOR EARLY ECONOMIC EVALUATIONS

 

Buisman L1, Rijnsburger A1, Van der Lugt A2, Redekop W1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus MC, Rotterdam, The Netherlands



15th Annual European Congress Index Page